<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005948</article-id><article-id pub-id-type="pmc">PMC11860833</article-id><article-id pub-id-type="doi">10.3390/vetsci12020189</article-id><article-id pub-id-type="publisher-id">vetsci-12-00189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Canine, Feline, and Murine Mammary Tumors as a Model for Translational Research in Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5650-6743</contrib-id><name><surname>Cassali</surname><given-names>Geovanni Dantas</given-names></name><xref rid="af1-vetsci-12-00189" ref-type="aff">1</xref><xref rid="c1-vetsci-12-00189" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Nakagaki</surname><given-names>Karen Yumi Ribeiro</given-names></name><xref rid="af1-vetsci-12-00189" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Salvi</surname><given-names>Marisa</given-names></name><xref rid="af1-vetsci-12-00189" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>dos Reys</surname><given-names>Marina Possa</given-names></name><xref rid="af1-vetsci-12-00189" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rocha</surname><given-names>Marcos Andr&#x000e9; Nino</given-names></name><xref rid="af2-vetsci-12-00189" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>de Campos</surname><given-names>Cecilia Bonolo</given-names></name><xref rid="af3-vetsci-12-00189" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1835-0303</contrib-id><name><surname>Ferreira</surname><given-names>Enio</given-names></name><xref rid="af1-vetsci-12-00189" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Angelica Cavalheiro Bertagnolli</given-names></name><xref rid="af4-vetsci-12-00189" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9676-7745</contrib-id><name><surname>dos Reis</surname><given-names>Diego Carlos</given-names></name><xref rid="af5-vetsci-12-00189" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2087-1690</contrib-id><name><surname>Damasceno</surname><given-names>Karine Araujo</given-names></name><xref rid="af6-vetsci-12-00189" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9879-7999</contrib-id><name><surname>Estrela-Lima</surname><given-names>Alessandra</given-names></name><xref rid="af2-vetsci-12-00189" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>van der Weyden</surname><given-names>Louise</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00189"><label>1</label>Departamento de Patologia Geral, Instituto de Ci&#x000ea;ncias Biol&#x000f3;gicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Minas Gerais, Brazil</aff><aff id="af2-vetsci-12-00189"><label>2</label>Escola de Medicina Veterin&#x000e1;ria e Zootecnia, Universidade Federal da Bahia, Salvador 40170-110, Bahia, Brazil</aff><aff id="af3-vetsci-12-00189"><label>3</label>Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada</aff><aff id="af4-vetsci-12-00189"><label>4</label>Instituto de Pesquisas Veterin&#x000e1;rias Desid&#x000e9;rio Finamor, Eldorado do Sul 92990-000, Rio Grande do Sul, Brazil</aff><aff id="af5-vetsci-12-00189"><label>5</label>Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK</aff><aff id="af6-vetsci-12-00189"><label>6</label>Centro de Pesquisas Gon&#x000e7;alo Moniz, Fiocruz, Salvador 40296-710, Bahia, Brazil</aff><author-notes><corresp id="c1-vetsci-12-00189"><label>*</label>Correspondence: <email>cassalig@icb.ufmg.br</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>189</elocation-id><history><date date-type="received"><day>16</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Mammary tumors are a major health concern in female dogs and cats, requiring standardized diagnostic criteria for better management. Animal models have been crucial in advancing the understanding of mammary cancer, benefiting both veterinary and human medicine. This review summarizes research from a specialized group in mammary pathology, categorizing studies into animal, experimental, and human research. Key topics include diagnosis, prognostic and predictive factors, tumor microenvironment, inflammation, treatment strategies, and tumor growth. The findings highlight the essential role of in vivo cancer models in studying tumor progression and therapeutic responses, contributing to both veterinary and human oncology.</p></abstract><abstract><title>Abstract</title><p>In veterinary medicine, mammary tumors are the most common neoplasms in female dogs and the third most frequent in cats, representing a significant challenge. Efforts have been directed toward adopting standardized diagnostic criteria to better understand tumor behavior and progression in these species. Meanwhile, the use of animal models has substantially advanced the understanding of comparative mammary carcinogenesis. These models provide critical insights into factors responsible for the disease in humans, with the expectation that such factors can be identified and controlled. In this context, this review presents a work based mainly on articles published by a research group specializing in mammary pathology (Laboratory of Comparative Pathology&#x02013;Department of General Pathology&#x02013;ICB/UFMG) and its collaborators, complementing their results with literature findings. The publications were categorized into animal research, experimental research, and human research. These studies addressed topics such as diagnosis, prognostic and predictive factors, tumor microenvironment, inflammation associated with tumors, treatment approaches, and factors influencing tumor growth. The conceptual network analysis underscores the importance of in vivo breast cancer models, both experimental and spontaneous, for understanding tumor progression mechanisms and therapeutic responses, offering valuable contributions to veterinary and human oncology.</p></abstract><kwd-group><kwd>mammary tumors</kwd><kwd>mammary cancer</kwd><kwd>histological grading</kwd><kwd>tumor microenvironment</kwd><kwd>translational models</kwd><kwd>cancer treatment</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00189"><title>1. Introduction</title><p>A strategy that has significantly advanced the understanding of various aspects of comparative mammary carcinogenesis is the use of animal models [<xref rid="B1-vetsci-12-00189" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00189" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00189" ref-type="bibr">3</xref>]. For this purpose, transmissible tumors, transplantable tumors, and, more recently, genetically modified animals have been employed [<xref rid="B1-vetsci-12-00189" ref-type="bibr">1</xref>,<xref rid="B3-vetsci-12-00189" ref-type="bibr">3</xref>]. The goal of cancer research in animal models is to achieve a deeper understanding of the factors responsible for the disease in humans, with the expectation that these factors can be identified, eliminated, or controlled. Information on the occurrence of spontaneous tumors primarily originates from veterinary research on tumors in domestic animals, wildlife, and animals kept in zoos and laboratories. The study of the most frequent tumors in animals provides epidemiological data and insights into their etiology, as well as biological and therapeutic materials for research.</p><p>Companion animals and humans share remarkably similar living environments, exposing both species to analogous toxic substances, viruses, and/or pollution. These external stimuli contribute to the development of cancer in both species through genetic/epigenetic alterations, metabolic disruptions, and/or immune-system-related changes [<xref rid="B4-vetsci-12-00189" ref-type="bibr">4</xref>,<xref rid="B5-vetsci-12-00189" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00189" ref-type="bibr">6</xref>,<xref rid="B7-vetsci-12-00189" ref-type="bibr">7</xref>].</p><p>In this context, mammary tumors are the most frequent neoplasms in female dogs and the third most common in cats, representing a significant challenge in veterinary medicine. Substantial efforts have been directed toward the adoption of standardized diagnostic criteria, understanding tumor behavior and progression, and evaluating prognostic and predictive factors in these neoplasms. The knowledge and adoption of these parameters are essential for selecting effective therapies that reduce tumor recurrence and improve overall survival rates.</p><p>The first phase of our research prioritized the characterization and classification of mammary tumors, clinical staging, histological grading, and the standardization of prognostic and predictive markers in mammary gland samples from dogs, based on criteria used in human medicine. In the second phase, we initiated projects focused on studying the tumor microenvironment and treating mammary gland tumors in dogs. Until then, treatment had been almost exclusively based on surgical excision. We tested and introduced novel therapeutic alternatives, particularly for advanced cases where surgery alone is often ineffective, aiming to provide patients with prolonged survival and a good quality of life.</p><p>This review will discuss the work of a research group specializing in mammary pathology (Laboratory of Comparative Pathology&#x02013;Department of General Pathology&#x02013;ICB/UFMG) and its collaborations. To that end, this review will address the following topics: diagnosis, prognostic and predictive factors, tumor microenvironment, inflammation associated with tumors, treatment, and factors that influence tumor growth. This group primarily employs murine experimental models (Ehrlich Tumor, 4T1, CTag) and spontaneous models (dogs and cats) to study breast cancer. The initial studies with spontaneous models began in 1994 and have sought to apply the criteria and classifications used in human medicine to veterinary medicine, inspired by the One Health concept and the belief that, <italic toggle="yes">&#x0201c;Between animal and human medicine, there are no dividing lines, nor should there be. The object is different, but the experience obtained forms the basis of all medicine.&#x0201d;&#x02013;Rudolf Virchow.</italic></p></sec><sec id="sec2-vetsci-12-00189"><title>2. Conceptual Mapping of Thematic Connections in Breast Cancer Research</title><p>The analysis of 174 articles published by the group led to the development of a comprehensive conceptual network based on 118 articles with a DOI. These articles were categorized into animal research (73 records), experimental research (44 records), and human research (1 record). <xref rid="vetsci-12-00189-f001" ref-type="fig">Figure 1</xref> illustrates this network, highlighting the main connections and emerging themes in breast cancer research.</p><p>Using the VosViewer software, we extracted bibliographic data to construct a network of concepts, which highlights the co-occurrences of relevant terms. VosViewer accesses the metadata of publications to identify and extract representative terms, forming a visual network that illustrates how these concepts interact. In this network, the sizes of the nodes indicate the levels of relevance of the terms, while the thicknesses of the lines represent the strengths of the interactions between the words.</p><p>The most prominent terms, such as mammary tumor, dog, mammary carcinoma, mouse, treatment, mixed tumor, human breast cancer, antitumor activity, comparative pathology, animal science, prognostic factors, veterinary medicine, histopathological analysis, and metastasis, reflect the predominant focuses of the scientific investigations (<xref rid="vetsci-12-00189-f001" ref-type="fig">Figure 1</xref>). These terms demonstrate how different areas of study are interrelated, emphasizing the complex and interconnected structure of the group&#x02019;s research.</p><p>The analysis of the conceptual network highlights the importance of in vivo breast cancer models, whether experimental or spontaneous, for understanding the mechanisms of tumor progression and therapeutic response. Continued advancement in this field is driven by interdisciplinary collaboration and translational research, integrating veterinary and medical oncology. This collaborative and integrated approach is essential to promote significant advances in breast cancer research.</p></sec><sec id="sec3-vetsci-12-00189"><title>3. Diagnosis</title><p>Mammary tumors in female dogs and cats exhibit epidemiological, clinical, biological, and genetic similarities to breast neoplasms in women and are thus considered important models in comparative studies [<xref rid="B7-vetsci-12-00189" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00189" ref-type="bibr">8</xref>,<xref rid="B9-vetsci-12-00189" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00189" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00189" ref-type="bibr">11</xref>,<xref rid="B12-vetsci-12-00189" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00189" ref-type="bibr">13</xref>]. Findings from our group demonstrate that the types of mammary tumors in humans, dogs, and cats are comparable, although the relative frequency of each tumor type differs [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00189" ref-type="bibr">15</xref>,<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>].</p><p>The incidence of spontaneous mammary tumors in female dogs is two to three times higher than that observed in women, and, similar to human species, mammary tumors are rare in males [<xref rid="B15-vetsci-12-00189" ref-type="bibr">15</xref>,<xref rid="B17-vetsci-12-00189" ref-type="bibr">17</xref>]. The approximate percentage of malignant breast neoplasms in women is 15% [<xref rid="B18-vetsci-12-00189" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-12-00189" ref-type="bibr">19</xref>], while in dogs and cats, it is around 85%, according to a recent survey carried out in Brazil (in which the total number of lesions evaluated in canines was 20,149 and in felines was 857) [<xref rid="B20-vetsci-12-00189" ref-type="bibr">20</xref>]. Regarding malignant tumors, a notable difference is observed: the most common carcinomas in women are invasive carcinomas of no special type, whereas in female dogs, the predominant types are carcinomas in mixed tumors, which, according to human classification, correspond to metaplastic breast carcinomas and carcinomas ex pleomorphic adenomas of the salivary gland [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B21-vetsci-12-00189" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-12-00189" ref-type="bibr">22</xref>]. Finally, when considering the frequency of other malignant neoplastic lesions of the mammary gland, such as sarcomas, it is evident that these are equally rare in both species [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>].</p><p>In addition to the similarities between canine, feline, and human mammary neoplasms, several studies suggest the presence of preneoplastic changes in the mammary tissue of female dogs that are comparable to those observed in women. Epithelial hyperplasia and columnar cell changes are recognized in human breast tissue as the early stages of cellular transformation leading to breast cancer [<xref rid="B23-vetsci-12-00189" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-12-00189" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00189" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-12-00189" ref-type="bibr">26</xref>]. The presence of these intraepithelial changes in dogs and their association with mammary neoplastic lesions support the use of the canine species as a comparative model for studying non-invasive mammary lesions and their progression to breast cancer. According to the literature, preneoplastic lesions exhibit cytological and structural compositions similar to those observed in human mammary tissue. Consistent with these findings, our group describes atypical ductal hyperplasia and atypical columnar cell changes as lesions with morphological and immunophenotypic characteristics compatible with the process of neoplastic transformation [<xref rid="B24-vetsci-12-00189" ref-type="bibr">24</xref>].</p><p>Several histological subtypes described in women have already been identified in female dogs and cats (<xref rid="vetsci-12-00189-t001" ref-type="table">Table 1</xref> and <xref rid="vetsci-12-00189-f002" ref-type="fig">Figure 2</xref>), including invasive micropapillary carcinoma, secretory carcinoma, and pleomorphic lobular carcinoma, among others [<xref rid="B27-vetsci-12-00189" ref-type="bibr">27</xref>,<xref rid="B28-vetsci-12-00189" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-12-00189" ref-type="bibr">29</xref>,<xref rid="B30-vetsci-12-00189" ref-type="bibr">30</xref>,<xref rid="B31-vetsci-12-00189" ref-type="bibr">31</xref>]. Invasive micropapillary carcinoma, although rare in both humans and dogs, exhibits distinct aggressive behavior and a poor prognosis. It has been observed that the clinicopathological and immunophenotypic characteristics, as well as overall survival, are similar between dogs and women. This subtype is characterized by aggressive behavior, high rates of metastasis to regional lymph nodes, and short overall survival [<xref rid="B32-vetsci-12-00189" ref-type="bibr">32</xref>]. As in humans, canine mammary cancer usually affects older individuals, with the average age being around 10 years, rarely occurring before 5 years of age [<xref rid="B33-vetsci-12-00189" ref-type="bibr">33</xref>] and, when using the Lebeau table, it appears that it occurs in the corresponding age groups [<xref rid="B34-vetsci-12-00189" ref-type="bibr">34</xref>].</p><p>Pleomorphic lobular carcinoma of the breast is a recognized subtype of invasive lobular carcinoma in humans. A significantly worse prognosis and survival rate are reported for the pleomorphic subtype. In female dogs, the same histological pattern, immunophenotypic characteristics, and aggressive behavior, including frequent metastasis to lymph nodes, have been identified [<xref rid="B28-vetsci-12-00189" ref-type="bibr">28</xref>].</p><p>Secretory carcinoma is a rare histological type first described in female dogs in 1999, with few subsequent reports [<xref rid="B27-vetsci-12-00189" ref-type="bibr">27</xref>,<xref rid="B35-vetsci-12-00189" ref-type="bibr">35</xref>]. In women, it is described as an uncommon variant of breast cancer, characterized by intracellular and extracellular eosinophilic secretions. Immunohistochemical findings in female dogs and cats are similar to those described for secretory carcinoma in humans, including positive staining for cytokeratin and lactalbumin [<xref rid="B36-vetsci-12-00189" ref-type="bibr">36</xref>]. In contrast to human patients, where this histological type exhibits limited aggressiveness, particularly in young patients, in dogs, it demonstrates aggressive behavior, with both regional and distant metastases [<xref rid="B27-vetsci-12-00189" ref-type="bibr">27</xref>,<xref rid="B37-vetsci-12-00189" ref-type="bibr">37</xref>].</p><p>In human medicine, basaloid carcinoma is described in the salivary gland and is morphologically similar to its benign counterpart, the basaloid adenoma [<xref rid="B36-vetsci-12-00189" ref-type="bibr">36</xref>]. In female dogs and cats, basaloid adenomas and carcinomas have been described in the mammary glands, exhibiting histological characteristics similar to those of human salivary glands [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B37-vetsci-12-00189" ref-type="bibr">37</xref>,<xref rid="B38-vetsci-12-00189" ref-type="bibr">38</xref>,<xref rid="B39-vetsci-12-00189" ref-type="bibr">39</xref>]. The malignant variant of this histological type appears to display aggressive behavior, with shorter survival times [<xref rid="B38-vetsci-12-00189" ref-type="bibr">38</xref>].</p><p>In our diagnostic routine, benign mixed tumors and carcinomas in mixed tumors are the most frequently diagnosed histological types in the mammary glands of female dogs and less frequently in cats. Together with carcinosarcomas and sarcomas in mixed tumors, they form a group characterized by a combination of epithelial (luminal and myoepithelial) and mesenchymal components with a variable matrix, which may be myxoid, chondroid, or osseous [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>]. According to a survey of mammary lesions diagnosed over 15 years at the Laboratory of Pathology, Federal University of Minas Gerais (UFMG), Brazil, mixed tumors account for 60% of the mammary neoplasms diagnosed [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>].</p><p>Histologically, benign mixed tumors are well-demarcated, composed of epithelial cell proliferation within a myxoid matrix with ectopic cartilage and bone formation. The epithelial cells are cuboidal or columnar, arranged in tubular or papillary patterns, and are lined by a layer of myoepithelial cells. The myxoid stroma contains spindle-shaped and stellate myoepithelial cells. Cartilage appears as nodules or plaques of variable size, with well-differentiated chondroblasts and chondrocytes. Osseous tissue consists of osteoblasts producing osteoid and mineralized bone [<xref rid="B40-vetsci-12-00189" ref-type="bibr">40</xref>,<xref rid="B41-vetsci-12-00189" ref-type="bibr">41</xref>,<xref rid="B42-vetsci-12-00189" ref-type="bibr">42</xref>,<xref rid="B43-vetsci-12-00189" ref-type="bibr">43</xref>,<xref rid="B44-vetsci-12-00189" ref-type="bibr">44</xref>].</p><p>Carcinomas in mixed tumors are characterized by carcinomatous proliferation, which can be in situ, microinvasive, or invasive, within benign mixed tumors. The carcinomatous proliferation may exhibit tubular, papillary, or micropapillary arrangements, or clusters and nests of cuboidal or columnar epithelial cells. Malignant epithelial cells are pleomorphic with atypical mitoses. Carcinosarcomas are composed of carcinomatous and sarcomatous proliferations. As observed in carcinomas in mixed tumors, the carcinomatous component may present in situ, microinvasive, or invasive proliferation with variable epithelial arrangements. The sarcomatous component consists of pleomorphic to polygonal cells resembling fibroblasts, osteocytes, and other mesenchymal tissues such as chondroid, adipose, and vascular tissue, exhibiting high cellularity, nuclear atypia, and an elevated mitotic index [<xref rid="B42-vetsci-12-00189" ref-type="bibr">42</xref>,<xref rid="B43-vetsci-12-00189" ref-type="bibr">43</xref>].</p><p>Given the high prevalence of mixed tumors and the heterogeneity of histological patterns, which can complicate diagnosis, our group has focused on standardizing morphological criteria and expanding knowledge about the histogenesis, malignant progression, and prognosis of these neoplasms.</p><p>In humans, benign mixed mammary tumors are rare; however, they are common neoplasms in the salivary glands, where they are referred to as pleomorphic adenomas [<xref rid="B45-vetsci-12-00189" ref-type="bibr">45</xref>]. In both cases, the epithelial component of these tumors can undergo malignant transformation, resulting in carcinomas in mixed tumors (in female dogs) or carcinomas ex pleomorphic adenomas (in human salivary glands) [<xref rid="B43-vetsci-12-00189" ref-type="bibr">43</xref>,<xref rid="B46-vetsci-12-00189" ref-type="bibr">46</xref>,<xref rid="B47-vetsci-12-00189" ref-type="bibr">47</xref>].</p><p>A comparative analysis between canine mammary mixed tumors and human salivary gland tumors revealed that both exhibit similar clinical, histological, and antigenic characteristics [<xref rid="B48-vetsci-12-00189" ref-type="bibr">48</xref>]. Another study found that the proportion of neoplasms with a luminal immunophenotype was comparable between carcinomas ex pleomorphic adenomas and carcinomas in mixed tumors [<xref rid="B49-vetsci-12-00189" ref-type="bibr">49</xref>]. These similarities highlight the applicability of canine mammary mixed tumors as comparative models for studying malignant transformation.</p><p>In general, female dogs with carcinomas in mixed tumors exhibit longer survival compared to those with other types of carcinomas [<xref rid="B50-vetsci-12-00189" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-12-00189" ref-type="bibr">51</xref>]. Conversely, female dogs with carcinosarcomas typically have a poorer prognosis compared to other types of mammary neoplasms due to high rates of nodal and distant metastasis [<xref rid="B50-vetsci-12-00189" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-12-00189" ref-type="bibr">51</xref>,<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>].</p><p>In a study conducted by our group that evaluated 162 benign mixed tumors, 682 carcinomas in mixed tumors, and 60 carcinosarcomas, it was observed that female dogs with benign mixed tumors presented smaller lesions (T1 and T2) compared to those with carcinosarcomas. Female dogs with benign mixed tumors were younger than those with carcinomas in mixed tumors or carcinosarcomas. The proportion of nodal or distant metastases was higher among dogs with carcinosarcomas compared to those with carcinomas in mixed tumors [<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>].</p><p>Interestingly, carcinomas in mixed tumors with micropapillary or solid proliferation patterns were associated with shorter survival compared to other proliferation patterns [<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>]. These findings demonstrate that carcinomatous areas in mixed tumors with more aggressive histological patterns can influence the behavior of these neoplasms. Therefore, a thorough evaluation of carcinoma in mixed tumors is essential to establish the prognosis. This is particularly important because female dogs with carcinomas in mixed tumors that exhibit areas of more aggressive histological types may benefit from adjuvant chemotherapy [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>,<xref rid="B53-vetsci-12-00189" ref-type="bibr">53</xref>].</p></sec><sec id="sec4-vetsci-12-00189"><title>4. Prognostic and Predictive Factors</title><p>In mammary tumors in dogs and cats, as in breast cancer in women, several clinical and pathological factors, such as tumor size, lymph node involvement, histological type, and grade, are evaluated to establish the clinical staging and determine the prognosis [<xref rid="B4-vetsci-12-00189" ref-type="bibr">4</xref>,<xref rid="B54-vetsci-12-00189" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-12-00189" ref-type="bibr">55</xref>,<xref rid="B56-vetsci-12-00189" ref-type="bibr">56</xref>,<xref rid="B57-vetsci-12-00189" ref-type="bibr">57</xref>,<xref rid="B58-vetsci-12-00189" ref-type="bibr">58</xref>]. Additionally, molecular markers are also assessed as sources of information to predict the prognosis in various types of cancers in female dogs, cats, and women [<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>,<xref rid="B60-vetsci-12-00189" ref-type="bibr">60</xref>,<xref rid="B61-vetsci-12-00189" ref-type="bibr">61</xref>]. In <xref rid="vetsci-12-00189-t002" ref-type="table">Table 2</xref>, we present the prognostic and predictive factors for canine, feline, and human mammary neoplasms.</p><p>The stage of mammary gland cancer is an important prognostic factor applied in women as well as in female dogs and cats. It is determined according to the TNM classification (primary tumor size, regional lymph node involvement, and distant metastasis). All individual characteristics of the TNM classification carry prognostic significance [<xref rid="B21-vetsci-12-00189" ref-type="bibr">21</xref>,<xref rid="B54-vetsci-12-00189" ref-type="bibr">54</xref>,<xref rid="B57-vetsci-12-00189" ref-type="bibr">57</xref>,<xref rid="B63-vetsci-12-00189" ref-type="bibr">63</xref>].</p><p>Tumor size, based on tumor diameter, is one of the most established factors for evaluating the breast cancer prognosis in women, as well as in female dogs and cats. Numerous studies confirm a correlation with shorter disease-free survival and overall survival in female dogs with large tumors (&#x0003e;5.0 cm) [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B64-vetsci-12-00189" ref-type="bibr">64</xref>]. However, it has been observed that even tumors smaller than 1.0 cm can be malignant and present metastasis at the time of diagnosis.</p><p>The definition of the histological type in malignant tumors, particularly mammary carcinomas, can be considered a prognostic parameter. Poorly differentiated mammary carcinomas, forming solid masses or even exhibiting organizational patterns distinct from normal mammary tissue, tend to have a poor or guarded prognosis [<xref rid="B41-vetsci-12-00189" ref-type="bibr">41</xref>].</p><p>In female dogs and cats, certain solid tumors, micropapillary carcinomas, and carcinosarcomas are recognized as aggressive tumors with a higher likelihood of metastasis development, and therefore a worse prognosis when considering the disease-free time and overall survival [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B37-vetsci-12-00189" ref-type="bibr">37</xref>].</p><p>In human medicine, the most widely used histological grading system for invasive carcinomas is the Nottingham system, which corresponds to the Scarff, Bloom, and Richardson (SBR) grading system [<xref rid="B65-vetsci-12-00189" ref-type="bibr">65</xref>], modified by Elston and Ellis (1998) [<xref rid="B66-vetsci-12-00189" ref-type="bibr">66</xref>]. These authors introduced the importance of the field diameter in assessing the mitotic index. In this system, the histological grade is based on the evaluation of tubular formation, nuclear pleomorphism, and mitotic count. The histological grade has been considered an independent prognostic indicator in human invasive breast cancer. A positive and significant correlation is observed between histological differentiation and the prognosis. Patients with poorly differentiated tumors (Grade III) have a shorter survival time compared to those with moderately (Grade II) and well-differentiated (Grade I) carcinomas [<xref rid="B66-vetsci-12-00189" ref-type="bibr">66</xref>]. The adaptation of this system for invasive carcinomas in female dogs and cats has shown results similar to those observed in humans [<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B67-vetsci-12-00189" ref-type="bibr">67</xref>,<xref rid="B68-vetsci-12-00189" ref-type="bibr">68</xref>,<xref rid="B69-vetsci-12-00189" ref-type="bibr">69</xref>,<xref rid="B70-vetsci-12-00189" ref-type="bibr">70</xref>,<xref rid="B71-vetsci-12-00189" ref-type="bibr">71</xref>,<xref rid="B72-vetsci-12-00189" ref-type="bibr">72</xref>].</p><p>The neoplastic involvement of regional lymph nodes is associated with a worse prognosis, as canine, feline, and human patients with lymph node involvement have a shorter survival time compared to those without lymph node metastasis [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B55-vetsci-12-00189" ref-type="bibr">55</xref>,<xref rid="B68-vetsci-12-00189" ref-type="bibr">68</xref>,<xref rid="B73-vetsci-12-00189" ref-type="bibr">73</xref>,<xref rid="B74-vetsci-12-00189" ref-type="bibr">74</xref>]. Similar to human breast cancer, a higher number of affected lymph nodes is also associated with a shorter survival time in female dogs and cats. However, there are few studies that analyze the sizes of metastases in lymph nodes, extracapsular extension, and their correlation with survival in female dogs [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B68-vetsci-12-00189" ref-type="bibr">68</xref>,<xref rid="B75-vetsci-12-00189" ref-type="bibr">75</xref>].</p><p>Although the majority of mammary pathology diagnosis is performed using hematoxylin- and eosin-stained sections, some cases require immunohistochemistry for a proper evaluation [<xref rid="B54-vetsci-12-00189" ref-type="bibr">54</xref>]. Molecular analysis in human oncology has been explored for decades, primarily aiming to establish diagnostic, prognostic, and predictive markers or to understand the mechanisms involved in carcinogenesis and breast cancer progression [<xref rid="B76-vetsci-12-00189" ref-type="bibr">76</xref>,<xref rid="B77-vetsci-12-00189" ref-type="bibr">77</xref>,<xref rid="B78-vetsci-12-00189" ref-type="bibr">78</xref>,<xref rid="B79-vetsci-12-00189" ref-type="bibr">79</xref>,<xref rid="B80-vetsci-12-00189" ref-type="bibr">80</xref>,<xref rid="B81-vetsci-12-00189" ref-type="bibr">81</xref>,<xref rid="B82-vetsci-12-00189" ref-type="bibr">82</xref>]. In veterinary medicine, this analysis is more recent and has been developed based on what is recommended for human medicine [<xref rid="B82-vetsci-12-00189" ref-type="bibr">82</xref>,<xref rid="B83-vetsci-12-00189" ref-type="bibr">83</xref>,<xref rid="B84-vetsci-12-00189" ref-type="bibr">84</xref>,<xref rid="B85-vetsci-12-00189" ref-type="bibr">85</xref>,<xref rid="B86-vetsci-12-00189" ref-type="bibr">86</xref>,<xref rid="B87-vetsci-12-00189" ref-type="bibr">87</xref>,<xref rid="B88-vetsci-12-00189" ref-type="bibr">88</xref>].</p><p>Immunohistochemical markers allow the determination of the presence of hormone receptors (estrogen receptor, progesterone receptor), the cell proliferation rate (Ki-67), angiogenesis (VEGF, CD31, CD34), and pro-angiogenic determinants such as the COX-2 enzyme, as well as the evaluation of markers indicative of tumor aggressiveness, such as the expression of receptors for epidermal growth factors (EGFR and HER-2) and transcriptional markers of proliferation and epithelial&#x02013;mesenchymal transition (c-Kit, cadherins, CD44, ZEB1 and 2, TWIST) in female dogs [<xref rid="B89-vetsci-12-00189" ref-type="bibr">89</xref>].</p><p>In human breast cancer, the greatest challenge in determining the prognosis is the heterogeneity of this type of neoplasia. Tumors with similar histological types, clinical stages, and differentiation grades may have different prognoses and therapeutic responses [<xref rid="B90-vetsci-12-00189" ref-type="bibr">90</xref>]. For this reason, different technologies have been used to stratify breast cancer types based on molecular similarities. Similarly, in female dogs and cats, a possible immunohistochemical classification of mammary carcinomas, referred to as &#x0201c;immunophenotypes (molecular profile)&#x0201d;, has been proposed. Based on this, carcinomas are categorized into five groups: luminal A, luminal B HER-2 negative, luminal B HER-2 positive, HER-2 overexpressed, and triple-negative/basal-like (<xref rid="vetsci-12-00189-t003" ref-type="table">Table 3</xref>). These tumors, classified into immunophenotypes, exhibit distinct clinical characteristics, and in addition to helping resolve tumor heterogeneity, they can infer the behavior and therapeutic response of the animals [<xref rid="B62-vetsci-12-00189" ref-type="bibr">62</xref>,<xref rid="B90-vetsci-12-00189" ref-type="bibr">90</xref>,<xref rid="B91-vetsci-12-00189" ref-type="bibr">91</xref>].</p><p>Estrogen and progesterone play a crucial role in mammary gland development, lactation, and tumorigenesis. Studies have demonstrated variations in the expression of receptors for these hormones during the development of mammary neoplasms. These variations seemingly have implications for patient prognosis in both dogs and cats [<xref rid="B89-vetsci-12-00189" ref-type="bibr">89</xref>]. Higher expression of these markers is observed in benign tumors compared to malignant ones [<xref rid="B92-vetsci-12-00189" ref-type="bibr">92</xref>]. In both species, lower estrogen receptor expression is found in poorly differentiated mammary carcinomas or more aggressive histological subtypes. In dogs, a relationship between lower estrogen expression, larger tumor masses, and shorter survival times has been described [<xref rid="B92-vetsci-12-00189" ref-type="bibr">92</xref>]. The evaluation of the combined expression of both hormone receptors, estrogen and progesterone, has been shown to better define the prognostic behavior of the patient. Tumors negative for both receptors have a worse prognosis compared to those positive for both or only one receptor.</p><p>In cats, most tumors exhibit high expression of estrogen and progesterone receptors; however, this expression does not correlate with aggressive histological parameters or overall survival after a mammary gland cancer diagnosis. This high hormonal expression, according to some authors, represents a potential avenue for future studies on hormone therapy [<xref rid="B48-vetsci-12-00189" ref-type="bibr">48</xref>].</p><p>The evaluation of cellular proliferative activity through immunohistochemical markers is recognized as an important prognostic parameter for mammary lesions in humans, dogs, and cats [<xref rid="B40-vetsci-12-00189" ref-type="bibr">40</xref>,<xref rid="B48-vetsci-12-00189" ref-type="bibr">48</xref>,<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>]. Higher immunostaining for Ki-67 is observed in malignant mammary neoplasms and is correlated with lower hormonal receptor expression, a higher tumor histological grade, a larger tumor size, the presence of metastases, and shorter survival times in both female dogs and cats [<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>,<xref rid="B93-vetsci-12-00189" ref-type="bibr">93</xref>].</p><p>HER2 (Human Epidermal Growth Factor Receptor 2) is a surface protein involved in cell growth. In breast cancer, overexpression of this protein (usually due to HER2 gene amplification) can occur and is associated with a more aggressive form of the disease [<xref rid="B21-vetsci-12-00189" ref-type="bibr">21</xref>]. The importance of HER2 as a prognostic and predictive factor in breast cancer is significant, as it helps guide treatment decisions and better understand tumor behavior [<xref rid="B55-vetsci-12-00189" ref-type="bibr">55</xref>]. In dogs and cats, HER2 is also considered an important tumor marker, regulating tumor growth, survival, and differentiation. In dogs, a positive correlation has been reported between HER2 expression and a high mitotic index, high histological grade, and the tumor size, although no relationship with survival has been identified [<xref rid="B69-vetsci-12-00189" ref-type="bibr">69</xref>].</p><p>In feline mammary carcinomas, HER2 expression is well-studied. HER2 in cats shows high homology with the human protein and is associated with increased cellular proliferation, the formation of large neoplastic masses, higher histological grades, and gene amplification of HER2. These findings support the idea that HER2 expression analysis may be considered a relevant prognostic factor [<xref rid="B57-vetsci-12-00189" ref-type="bibr">57</xref>].</p><p>Cyclooxygenases are enzymes that catalyze the conversion of arachidonic acid into a variety of prostaglandins. There are two cyclooxygenase isoforms, COX-1 and COX-2. COX-2 is the isoform most frequently studied in relation to neoplastic development and progression, as it is directly linked to tumor angiogenesis. Increased immunohistochemical expression of COX-2 is associated with unfavorable prognostic factors such as a larger tumor size, more aggressive histological subtypes, higher metastatic potential to lymph nodes, and high histological grade. COX-2 is also considered an important predictive factor in canine and feline mammary carcinomas [<xref rid="B57-vetsci-12-00189" ref-type="bibr">57</xref>,<xref rid="B94-vetsci-12-00189" ref-type="bibr">94</xref>]. A recent comparative study on micropapillary carcinomas in dogs and women revealed similar patterns of COX-2 expression between the two species [<xref rid="B95-vetsci-12-00189" ref-type="bibr">95</xref>].</p><p>Tumor markers are substances present in tumors, the blood, or other biological fluids, primarily produced by neoplastic cells or normal tissue in response to the presence of the tumor. Serum tumor markers, which until recently were primarily studied in human neoplasms, have gained significant importance in veterinary medicine. The serum markers CEA, CA15.3, and LDH have been studied in dogs with and without mammary neoplasms and were measurable in all groups (healthy, with metastases, and without metastases in lymph nodes). Higher serum concentrations of CA15.3 and LDH were associated with regional and distant metastases. A significantly higher serum concentration of CA15.3 was found in animals with lymph node metastases compared to those without metastases. No significant differences in CEA levels were observed between groups [<xref rid="B96-vetsci-12-00189" ref-type="bibr">96</xref>].</p></sec><sec id="sec5-vetsci-12-00189"><title>5. Tumoral Microenvironment</title><p>Recent studies have highlighted that breast cancer is not solely composed of neoplastic cells but also involves significant modifications in the surrounding stroma, known as the tumor microenvironment. These changes play a pivotal role in the development and progression of breast cancer and present potential opportunities for therapeutic intervention. Key components of the tumor microenvironment, such as immunosuppressive cells, soluble factors, and an altered extracellular matrix, collaborate to suppress antitumor immune responses and drive tumor progression and metastasis. The stromal cells within the breast cancer microenvironment undergo molecular changes and exhibit abnormal signaling pathways, some of which are valuable predictors of clinical outcomes. The tumor microenvironment (TME) has gained significant attention in research due to its complex cellular and non-cellular composition, which can profoundly influence the diagnosis, prognosis, and treatment of breast cancer patients [<xref rid="B97-vetsci-12-00189" ref-type="bibr">97</xref>,<xref rid="B98-vetsci-12-00189" ref-type="bibr">98</xref>,<xref rid="B99-vetsci-12-00189" ref-type="bibr">99</xref>].</p><sec id="sec5dot1-vetsci-12-00189"><title>5.1. Preclinical Studies In Vitro and in Animal Models</title><p>Among the research lines developed by the group, preclinical studies on the tumor microenvironment in experimental models have made significant contributions to oncology.</p><p>One study focused on tumor cell heterogeneity, a critical factor in determining therapy responses and tumor progression, emphasizing the importance of molecular profiling to identify therapeutic targets and vulnerabilities in cancer treatment. The research evaluated cellular heterogeneity in triple-negative breast cancer (TNBC) cell lines BT-549 and Hs 578T, cultured in monolayer and tumor sphere models. Fluorescence and electron microscopy, along with flow cytometry analysis, revealed substantial morphological and phenotypic variation both within and between these cell lines, characterized by mesenchymal traits such as the absence of E-cadherin and the formation of filopodia [<xref rid="B100-vetsci-12-00189" ref-type="bibr">100</xref>].</p><p>Additionally, the transcription factor SOX3 was found to play a pivotal role in regulating epithelial markers, promoting E-cadherin (ECAD) expression while suppressing N-cadherin (NCAD), SNAIL, ZEB1, and ZEB2, thereby maintaining epithelial characteristics in breast cancer cells. SOX3 also enhanced apoptosis in MDA-MB-231 cells, with its low expression associated with reduced apoptosis in ductal carcinomas. These findings highlight the tumor-suppressive potential of SOX3, warranting further investigation [<xref rid="B101-vetsci-12-00189" ref-type="bibr">101</xref>].</p><p>A robust line of research has focused on exploring the diverse factors influencing cancer progression using experimental models such as Ehrlich tumors and the murine mammary carcinoma 4T1. These studies aim to contribute to the understanding of the tumor microenvironment, progression, metastasis, and the development of antineoplastic therapies.</p><p>The 4T1 murine mammary carcinoma is a model of triple-negative breast cancer that exhibits rapid and progressive metastatic development when orthotopically and heterotopically inoculated in BALB/c mice [<xref rid="B96-vetsci-12-00189" ref-type="bibr">96</xref>]. The metastases in this model display a distribution similar to that of human and canine mammary glands, with the lungs, liver, bones, and brain being the main metastatic sites. Furthermore, tumor development in this model leads to significant changes in both the primary and metastatic tumor microenvironments, with a notable accumulation of various immune response cells associated with alterations in extracellular matrix components and angiogenesis [<xref rid="B97-vetsci-12-00189" ref-type="bibr">97</xref>,<xref rid="B98-vetsci-12-00189" ref-type="bibr">98</xref>].</p><p>In addition to the 4T1 murine mammary carcinoma, we also extensively use the Ehrlich tumor for experimental therapeutic studies [<xref rid="B49-vetsci-12-00189" ref-type="bibr">49</xref>,<xref rid="B102-vetsci-12-00189" ref-type="bibr">102</xref>,<xref rid="B103-vetsci-12-00189" ref-type="bibr">103</xref>,<xref rid="B104-vetsci-12-00189" ref-type="bibr">104</xref>,<xref rid="B105-vetsci-12-00189" ref-type="bibr">105</xref>,<xref rid="B106-vetsci-12-00189" ref-type="bibr">106</xref>,<xref rid="B107-vetsci-12-00189" ref-type="bibr">107</xref>,<xref rid="B108-vetsci-12-00189" ref-type="bibr">108</xref>,<xref rid="B109-vetsci-12-00189" ref-type="bibr">109</xref>]. The Ehrlich tumor is a transplantable tumor originating from the mammary glands of female mice, which grows in an ascitic form when inoculated into the peritoneum or in a solid form, typically inoculated into the mammary gland, flank, and paws [<xref rid="B108-vetsci-12-00189" ref-type="bibr">108</xref>,<xref rid="B110-vetsci-12-00189" ref-type="bibr">110</xref>].</p><p>The influence of allergic conditions on the progression of Ehrlich tumors was also studied. The research showed that chronic antigen ingestion by sensitized mice resulted in reduced tumor progression, mediated by increased cellular apoptosis and reduced necrotic areas. These findings suggest a potential protective mechanism in allergic individuals [<xref rid="B109-vetsci-12-00189" ref-type="bibr">109</xref>].</p><p>The research also evaluated the efficacy of the recombinant protein Kint3-4 in inhibiting tumor growth and angiogenesis in Ehrlich tumors. Mice treated with Kint3-4 exhibited reduced tumor growth, decreased inflammation, and a lower microvessel density, demonstrating a significant antiproliferative effect compared to the control group [<xref rid="B103-vetsci-12-00189" ref-type="bibr">103</xref>]. Additionally, the expression of Qa-2 in solid Ehrlich tumors and its relationship with the profile of infiltrating lymphocytes were analyzed. It was observed that Qa-2 expression increased during intermediate stages of tumor development and continued to rise in later stages, correlating with an increase in CD3+ cells. This finding suggests that Qa-2 may play a relevant immunomodulatory role in tumor progression [<xref rid="B108-vetsci-12-00189" ref-type="bibr">108</xref>].</p><p>The studies conducted by this research group have significantly advanced the understanding of the molecular and cellular mechanisms associated with breast cancer, utilizing both the Ehrlich tumor and the murine 4T1 model. A noteworthy focus was the evaluation of the antineoplastic effects of thalidomide. The results demonstrated thalidomide&#x02019;s remarkable capacity to reduce tumor growth and pulmonary metastasis in this model. Thalidomide exerted its effects by suppressing critical processes such as angiogenesis and inflammation, evidenced by reduced blood vessel formation and lower levels of pro-inflammatory factors [<xref rid="B110-vetsci-12-00189" ref-type="bibr">110</xref>].</p><p>In addition, the effects of thalidomide on 4T1 mammary carcinoma were evaluated from a hematological perspective. The therapy led to a significant increase in circulating leukocyte counts, which, interestingly, coincided with reduced tumor growth, suggesting a possible link between immune response activation and tumor inhibition. Another aspect explored was the immunomodulatory role of thalidomide, particularly concerning tumor-associated macrophages (TAMs). The treatment not only reduced primary tumor size and pulmonary metastasis but also influenced TAM infiltration, indicating that different doses of thalidomide may variably modulate the tumor microenvironment [<xref rid="B111-vetsci-12-00189" ref-type="bibr">111</xref>].</p></sec><sec id="sec5dot2-vetsci-12-00189"><title>5.2. Studies in Canine Models</title><p>Research involving canine models has provided valuable insights into the tumor microenvironment, cancer progression, and therapeutic interventions, with a focus on translational applications to human oncology. One line of investigation explored the molecular and cellular characteristics of canine mammary tumors, particularly mixed mammary tumors (CMTs). These studies highlighted the role of the extracellular matrix, immune infiltration, and stromal composition in tumor behavior.</p></sec><sec id="sec5dot3-vetsci-12-00189"><title>5.3. Tumor Stroma</title><p>In the pursuit of a better understanding of the tumor microenvironment, the stroma and its components have been extensively studied. The extracellular matrix is a key element of the tumor microenvironment. Beyond providing structural support for the growth of solid tumors, it is directly involved in cellular proliferation, differentiation, migration, and tumor progression.</p><p>In this context, the characterization of mesenchymal components in canine mixed mammary tumors has been a focus of research. Auler et al. (2011) [<xref rid="B112-vetsci-12-00189" ref-type="bibr">112</xref>] evaluated benign mixed tumors and carcinomas within mixed tumors (CMTs) and observed that myeloid metaplasia is associated with the presence of blood capillaries and megakaryocytes but is not linked to the benign or malignant nature of the tumors.</p><p>The components of the extracellular matrix have also been studied to elucidate the mechanisms underlying the biological behavior of tumors. Damasceno et al. (2012) [<xref rid="B113-vetsci-12-00189" ref-type="bibr">113</xref>] were the first to investigate the expression of versican in in situ and invasive carcinomatous regions of canine CMTs and to evaluate potential associations between versican expression, classical prognostic factors, and overall survival. In this study, the confirmation of invasive areas was conducted by identifying the loss of staining for p63 and smooth muscle &#x003b1;-actin (&#x003b1;-SMA) in canine CMT cases. Versican immunoreactivity was found to be less intense in areas adjacent to in situ carcinomatous regions compared to invasive regions, which exhibited extensive and strong staining, suggesting a direct relationship between versican and tumor invasiveness.</p><p>The expression of versican and its relationship with p63 and &#x003b1;-SMA were further evaluated in myoepithelial cells at different stages of differentiation in canine mixed mammary tumors [<xref rid="B114-vetsci-12-00189" ref-type="bibr">114</xref>]. A significant variation in versican expression was observed across different stages of myoepithelial cell differentiation, with an inverse correlation between versican and p63/&#x003b1;-SMA expression. Specifically, spindle-shaped or stellate myoepithelial cells producing myxoid matrix showed lower p63/&#x003b1;-SMA expression and higher versican expression, indicating that dedifferentiation was associated with increased production of this proteoglycan in the matrix.</p><p>The critical role of myoepithelial cells in versican production within mixed tumors was further demonstrated by Figueiredo et al. (2021) [<xref rid="B115-vetsci-12-00189" ref-type="bibr">115</xref>]. This study revealed that versican expression was similarly associated with invasiveness in carcinomas with and without myoepithelial proliferation. However, higher levels of versican were observed in CMTs, suggesting that the presence of myoepithelial cells in this tumor type contributes to the stromal composition and promotes increased versican expression.</p><p>We then sought to understand the relationship between the proteoglycan versican and the receptors CD44 and the EGFR family, which are expressed on the membrane of carcinomatous cells and identified as key mediators linking versican to tumor cells [<xref rid="B116-vetsci-12-00189" ref-type="bibr">116</xref>]. The study suggests that the coexpression of versican with these receptors is associated with more aggressive characteristics of mammary tumors in female dogs, indicating that versican may play a significant role in tumor progression. The analysis of these proteins provided valuable insights for the prognosis and treatment of these tumors.</p><p>This relationship between versican and EGFR/HER-2 was further explored by Damasceno et al. (2016) [<xref rid="B117-vetsci-12-00189" ref-type="bibr">117</xref>]. In this investigation, it was demonstrated that tumors with low versican expression exhibited higher EGFR staining in in situ areas, whereas tumors with high versican expression displayed increased staining for both EGFR and HER-2 in in situ areas. These findings suggest that these molecules may play a critical role during the early stages of tumor progression.</p><p>Rodrigues and collaborators (2016) [<xref rid="B118-vetsci-12-00189" ref-type="bibr">118</xref>] investigated the subcellular localization of epidermal growth factor receptor (EGFR) in invasive micropapillary carcinoma (IMPC) of the canine mammary gland using confocal immunofluorescence microscopy. Their study revealed that EGFR co-localized with the inner nuclear envelope marker Lamin B1 in this tumor, suggesting that EGFR localization may serve as a predictive biomarker for a therapeutic response in IMPC. Subsequently, these authors [<xref rid="B119-vetsci-12-00189" ref-type="bibr">119</xref>] characterized the neoplastic cells outlining the cystic spaces of IMPC in canine mammary glands using immunohistochemistry (IHC), immunofluorescence (IF), super-resolution microscopy, and transmission electron microscopy (TEM). Their analysis provided insights into the cellular composition of the cystic areas. The loss of epithelial cell polarity in IMPC was demonstrated by the mislocalization of MUC1 to the stroma-facing surface. Additionally, the cystic spaces were shown to be lined by myoepithelial-like cells that had lost p63 expression. These findings contribute to a deeper understanding of the cellular microenvironment in invasive tumors, offering potential advancements in cancer diagnosis and treatment.</p><p>Second harmonic generation and multiphoton excitation fluorescence microscopy were utilized to evaluate collagen fiber alterations in human and canine mammary neoplasms [<xref rid="B120-vetsci-12-00189" ref-type="bibr">120</xref>]. The analysis demonstrated a lower density of collagen fibers and a higher density of cells in both human and canine mammary carcinomas compared to normal tissue, with collagen fibers being more aligned in tumors. Shorter collagen fibers were observed in carcinomas with an unfavorable prognosis, correlating with clinical and pathological data in both species. Subsequently, we investigated collagen modifications that predict lymphatic metastasis in dogs with carcinomas in mixed mammary tumors. Carcinomas with lymph node metastasis (CMTMs) exhibited shorter, more wavy collagen fibers compared to carcinomas without lymph node metastasis (CMTs), underscoring the critical role of collagen in invasion and the dissemination of lymphatic metastasis [<xref rid="B121-vetsci-12-00189" ref-type="bibr">121</xref>].</p></sec><sec id="sec5dot4-vetsci-12-00189"><title>5.4. Tumor-Associated Inflammation</title><p>Mammary neoplasms in women, dogs, and cats are characterized by the infiltration of a variety of immune cells, which play critical roles in both promoting and inhibiting tumor growth, significantly impacting prognosis [<xref rid="B122-vetsci-12-00189" ref-type="bibr">122</xref>,<xref rid="B123-vetsci-12-00189" ref-type="bibr">123</xref>,<xref rid="B124-vetsci-12-00189" ref-type="bibr">124</xref>]. In human breast cancer, the tumor microenvironment (TME) contains cells that can determine the prognosis. CD8+ T cells, natural killer (NK) cells, M1 macrophages, and dendritic cells are associated with favorable outcomes as they secrete tumor-inhibiting factors and cytokines that stimulate the immune system, inhibiting angiogenesis and tumor metastasis [<xref rid="B125-vetsci-12-00189" ref-type="bibr">125</xref>,<xref rid="B126-vetsci-12-00189" ref-type="bibr">126</xref>,<xref rid="B127-vetsci-12-00189" ref-type="bibr">127</xref>,<xref rid="B128-vetsci-12-00189" ref-type="bibr">128</xref>].</p><p>Conversely, cells such as M2 macrophages, cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs), tumor-associated endothelial cells (TECs), pericytes, mesenchymal stem cells (MSCs), and cancer-associated adipocytes (CAAs) contribute to an environment that favors tumor progression [<xref rid="B129-vetsci-12-00189" ref-type="bibr">129</xref>,<xref rid="B130-vetsci-12-00189" ref-type="bibr">130</xref>,<xref rid="B131-vetsci-12-00189" ref-type="bibr">131</xref>,<xref rid="B132-vetsci-12-00189" ref-type="bibr">132</xref>,<xref rid="B133-vetsci-12-00189" ref-type="bibr">133</xref>,<xref rid="B134-vetsci-12-00189" ref-type="bibr">134</xref>,<xref rid="B135-vetsci-12-00189" ref-type="bibr">135</xref>,<xref rid="B136-vetsci-12-00189" ref-type="bibr">136</xref>]. Additionally, there are cellular compositions whose predictive role is complex and not yet fully elucidated, sometimes promoting while other times inhibiting neoplastic growth, such as regulatory T cells (Tregs), B cells, CD4+ T cells, and tumor-associated neutrophils (TANs) [<xref rid="B135-vetsci-12-00189" ref-type="bibr">135</xref>,<xref rid="B136-vetsci-12-00189" ref-type="bibr">136</xref>,<xref rid="B137-vetsci-12-00189" ref-type="bibr">137</xref>,<xref rid="B138-vetsci-12-00189" ref-type="bibr">138</xref>].</p><p>The majority of infiltrating leukocytes in breast tumors are lymphocytes [<xref rid="B121-vetsci-12-00189" ref-type="bibr">121</xref>]. Studies indicate that intense lymphocytic infiltrates correlate with favorable prognoses, especially in molecular subtypes like triple-negative (TNBC) and HER2+ [<xref rid="B139-vetsci-12-00189" ref-type="bibr">139</xref>]. Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with responses to cytotoxic treatments and immunotherapy, particularly for patients with triple-negative breast cancer [<xref rid="B140-vetsci-12-00189" ref-type="bibr">140</xref>]. However, the presence of lymphocyte subpopulations such as Tregs can indicate unfavorable prognoses due to their ability to suppress antitumor responses.</p><p>Malignant mammary tumors in dogs are also characterized by significant infiltration of mononuclear cells, particularly lymphocytes, whereas lymphocytes are rarely observed in normal mammary glands and benign mammary tumors [<xref rid="B123-vetsci-12-00189" ref-type="bibr">123</xref>]. High-grade tumors with lymphatic invasion exhibit greater infiltration by Tregs, which is associated with a poorer prognosis, lower survival, and more aggressive disease characteristics [<xref rid="B141-vetsci-12-00189" ref-type="bibr">141</xref>].</p><p>Regarding macrophage infiltration in mammary tumors, in both human and canine patients, their increased presence without distinction in the activation profile can be related to better clinical staging, grading, higher expression of class I MHC molecules in circulating monocytes, and overall survival. However, a significant presence of M2 macrophages is related to more aggressive clinicopathological characteristics, such as lymph node metastasis, a shorter survival time, and a poorer prognosis. In mammary carcinomas of women and dogs, inflammatory infiltrates that relate to a better response to chemotherapy show a predominance of pro-inflammatory (M1) macrophages, whereas poorer survival is associated with anti-inflammatory (M2) macrophages.</p><p>Similar to mammary tumors in women and dogs, in feline mammary carcinomas, CD3+ T lymphocytes represent the main immune-infiltrating subpopulation. High infiltration of CD3+ T cells combined with CD8+ T lymphocytes and tumor-associated macrophages (TAMs) of the M1 subtype suggest better outcomes in cats with triple-negative tumors [<xref rid="B97-vetsci-12-00189" ref-type="bibr">97</xref>]. CD8+ T cells constitute a new favorable prognostic factor. B lymphocytes constitute a significant portion of the lymphocyte population, and along with plasma cells, are observed more frequently in smaller tumors without lymphatic invasion or lower grading, indicating a relationship with the biological behavior of the tumor and suggesting a possible protective effect of these cells or their presence in the early phase of tumor development [<xref rid="B97-vetsci-12-00189" ref-type="bibr">97</xref>]. On the other hand, regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) of the M2 subtype have been linked to immunosuppression, tumor progression, undifferentiated tumors, more aggressive behavior, promotion of angiogenesis, modulation of the extracellular matrix, and poorer disease-free survival (DFS) and overall survival (OS) rates [<xref rid="B97-vetsci-12-00189" ref-type="bibr">97</xref>,<xref rid="B124-vetsci-12-00189" ref-type="bibr">124</xref>,<xref rid="B142-vetsci-12-00189" ref-type="bibr">142</xref>]. Additionally, elevated neutrophil-to-lymphocyte ratio (NLR) levels have been correlated with unfavorable outcomes, suggesting they are an important indicator of the intensity of the inflammatory process [<xref rid="B143-vetsci-12-00189" ref-type="bibr">143</xref>].</p><p>In experimental models using rodents, primary tumors have been observed to activate &#x0201c;tumor-entrained neutrophils&#x0201d;, which may inhibit the targeting of metastases to the lungs [<xref rid="B144-vetsci-12-00189" ref-type="bibr">144</xref>] and can reduce the proliferation of CD8+ T lymphocytes; however, their role in human and veterinary medicine remains uncertain [<xref rid="B135-vetsci-12-00189" ref-type="bibr">135</xref>].</p><p>Recognizing cellular heterogeneity in the tumor microenvironment can guide personalized therapeutic strategies, enhancing treatment efficacy and improving the prognosis in both humans and animals. To improve understanding of the role of immune infiltration in mammary tumors, our group has conducted several studies with dogs over the years. In 2010, Estrela-Lima et al. [<xref rid="B145-vetsci-12-00189" ref-type="bibr">145</xref>] evaluated the immunophenotypic profile of infiltrating lymphocytes in canine mammary carcinomas, aiming to associate them with prognostic factors and survival rates. It was concluded that analyzing this profile can offer a valuable tool for predicting the prognosis in dogs with mammary carcinoma. The intensity of lymphocytic infiltration and the balance between CD4+ and CD8+ T lymphocytes emerge as potential prognostic biomarkers that can guide clinical and therapeutic decisions. These findings underscore the importance of considering the tumor&#x02019;s immunological microenvironment in managing canine mammary gland cancer, which holds promise for similar research in human breast cancer.</p><p>In 2018, Souza et al. [<xref rid="B146-vetsci-12-00189" ref-type="bibr">146</xref>] investigated the density of inflammatory cells and the percentage of tumor fibrosis in canine mammary neoplasms, relating these parameters to different histological types. It was found that the composition of the inflammatory infiltrate and the presence of tumor fibrosis are critical factors in determining the aggressiveness of mammary tumors. A high density of neutrophils and plasma cells may indicate an unfavorable prognosis, while the presence of macrophages and CD8+ T lymphocytes is associated with a more positive prognosis.</p><p>Also in 2018, Vieira-Filho et al. [<xref rid="B147-vetsci-12-00189" ref-type="bibr">147</xref>] evaluated the density of tumor-associated macrophages (TAMs) in the mammary carcinoma microenvironment and the expression of SOCS1 and SOCS3 proteins. It was concluded that the expression of SOCS3 in activated macrophages is associated with an effective antitumor immune response, better clinical parameters, and higher survival rates. In contrast, activation related to SOCS1 was associated with tumor progression and reduced survival rates. These results suggest that SOCS proteins play a role in modulating the immune response in the tumor microenvironment, directly influencing the prognosis of mammary neoplasms.</p><p>In the same year, Monteiro et al. [<xref rid="B148-vetsci-12-00189" ref-type="bibr">148</xref>] studied the relationship of TAMs with tumor progression and macrophage polarization into M1 and M2 subtypes in canine mammary tumors. The study concluded that TAMs play an important role in the progression and aggressiveness of these tumors. Macrophage polarization to the M2 phenotype is associated with a more permissive tumor microenvironment, favoring tumor growth and invasion. These findings suggest that TAMs, especially the M2 subtype, may serve as therapeutic targets to improve the prognosis in dogs with breast cancer.</p><p>In 2022, Damasceno and colleagues [<xref rid="B149-vetsci-12-00189" ref-type="bibr">149</xref>] analyzed immune evasion mechanisms in dogs with inflammatory mammary carcinoma. It was concluded that inflammatory mammary carcinoma is associated with an altered immune response, characterized by intense lymphocytic infiltration and increased but ineffective cytotoxic activity. Low expression of FAS-L and a high presence of macrophages contribute to immune evasion and aggressive tumor progression.</p><p>Recently, Flecher et al. [<xref rid="B150-vetsci-12-00189" ref-type="bibr">150</xref>] characterized the immunophenotype and degree of inflammation in solid-type canine mammary neoplasms, investigating their association with metastasis, the Ki-67 index, tumor size, necrosis, and survival. The study concluded that the immunophenotype and inflammation level are critical factors in determining the prognosis of mammary neoplasms. As expected, neoplasms with a triple-negative immunophenotype exhibited greater aggressiveness and shorter survival times. These findings suggest that a detailed assessment of the immunological and inflammatory profile is essential for the clinical and therapeutic management of mammary neoplasms, contributing to a more personalized and effective approach to combating breast cancer.</p><p>The favorable and unfavorable prognostic aspects of the tumoral microenvironment in the described species are summarized in <xref rid="vetsci-12-00189-f003" ref-type="fig">Figure 3</xref>.</p></sec></sec><sec id="sec6-vetsci-12-00189"><title>6. Treatment and Factors Influencing Tumor Growth</title><p>The study of cancer biology has provided numerous possibilities for diagnosis and therapeutic strategies while simultaneously revealing its enormous complexity, which impairs the clinical success of many therapies. These challenges include tumor microenvironment (TME) complexities, intra- and extra-tumoral molecular and biological heterogeneity, differences in metabolic and immune responses, and the presence of drug-resistant cancer stem cells capable of repopulating cancers subjected prior to therapies [<xref rid="B151-vetsci-12-00189" ref-type="bibr">151</xref>].</p><p>In this context, our efforts have focused on understanding the TME in breast cancer, using spontaneous, induced, or xenograft murine models of breast cancer [<xref rid="B109-vetsci-12-00189" ref-type="bibr">109</xref>,<xref rid="B110-vetsci-12-00189" ref-type="bibr">110</xref>,<xref rid="B120-vetsci-12-00189" ref-type="bibr">120</xref>,<xref rid="B152-vetsci-12-00189" ref-type="bibr">152</xref>] and spontaneous mammary tumors in dogs and cats [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B104-vetsci-12-00189" ref-type="bibr">104</xref>,<xref rid="B119-vetsci-12-00189" ref-type="bibr">119</xref>,<xref rid="B146-vetsci-12-00189" ref-type="bibr">146</xref>,<xref rid="B147-vetsci-12-00189" ref-type="bibr">147</xref>,<xref rid="B149-vetsci-12-00189" ref-type="bibr">149</xref>].</p><p>Driven by our studies, collaborators, and others eliciting key molecular and cellular pathways associated with tumor progression in breast cancer, therapeutic studies were conducted to identify new treatment protocols using drugs already approved by international and federal regulatory bodies or to identify new compounds with antitumor activity.</p><p>Thalidomide is a drug with antiangiogenic, immunomodulatory, and anti-inflammatory properties that has been approved for the treatment of refractory multiple myeloma in humans, as well as other inflammatory diseases [<xref rid="B149-vetsci-12-00189" ref-type="bibr">149</xref>,<xref rid="B153-vetsci-12-00189" ref-type="bibr">153</xref>,<xref rid="B154-vetsci-12-00189" ref-type="bibr">154</xref>]. Our studies have demonstrated that thalidomide treatment promoted a reduction in metastatic tumor burden of the 4T1 tumor, associated with leukocytosis, decreased tumor inflammation and angiogenesis, a reduction in tumor-associated macrophages (TAMs) in the primary tumor, and an increase in these cells in metastasis-affected lungs [<xref rid="B116-vetsci-12-00189" ref-type="bibr">116</xref>,<xref rid="B117-vetsci-12-00189" ref-type="bibr">117</xref>,<xref rid="B155-vetsci-12-00189" ref-type="bibr">155</xref>]. However, in canine mammary carcinomas, the antitumor and anti-angiogenic effects of thalidomide were not observed [<xref rid="B156-vetsci-12-00189" ref-type="bibr">156</xref>]. Indeed, in a phase II clinical trial in humans, thalidomide showed little to no antitumor effect in metastatic breast cancer [<xref rid="B157-vetsci-12-00189" ref-type="bibr">157</xref>]. This highlights the limitations of translating therapeutic studies of this drug from xenograft murine models to human and veterinary medicine. Nevertheless, studies combining thalidomide with chemotherapy, particularly carboplatin, have proven effective in both the 4T1 murine model and canine mammary carcinomas [<xref rid="B156-vetsci-12-00189" ref-type="bibr">156</xref>].</p><p>In studies involving Ehrlich tumors, the impact of thyroid hormones on tumor growth was investigated in both solid and ascitic forms in adult female mice, both ovariectomized and non-ovariectomized. The findings indicated that hypothyroidism delayed tumor progression in both forms while maintaining cellular characteristics indicative of high proliferative potential and malignancy. Interestingly, ovariectomy alone caused only minor alterations, but when combined with hypothyroidism, it significantly enhanced the delay in tumor growth [<xref rid="B105-vetsci-12-00189" ref-type="bibr">105</xref>,<xref rid="B158-vetsci-12-00189" ref-type="bibr">158</xref>]. In contrast, hyperthyroidism led to a significant increase in tumor size in non-ovariectomized mice, with a less pronounced effect in ovariectomized mice [<xref rid="B105-vetsci-12-00189" ref-type="bibr">105</xref>].</p><p>The impact of natural extracts on tumor progression has also been a significant area of investigation. The aqueous extract of <italic toggle="yes">Agaricus blazei</italic> Murill was assessed for its effects on tumor growth and lymph node metastasis. While an initial reduction in tumor growth was noted, no significant differences were observed in relative tumor weight or proliferation rates between treated and untreated mice. Metastases were detected in the lymph nodes of all mice [<xref rid="B159-vetsci-12-00189" ref-type="bibr">159</xref>]. Similarly, ethanolic and aqueous extracts of <italic toggle="yes">Arrabidaea chica</italic> demonstrated efficacy in reducing tumor progression following oral administration, with notable effects on hematological profiles, including neutrophil counts, globulin levels, and the proportions of CD4+ and CD8+ lymphocytes [<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>]. These findings underline the critical role of inflammation in the progression of Ehrlich tumors in mice.</p><p>Other systemic factors, such as high-sugar and high-fat diets, also play a significant role in the pathogenesis of breast cancer. Diets rich in sugar and fat have been shown to influence immune responses and promote tumor growth in a murine model of 7,12-dimethylbenz[a]anthracene (DMBA)/medroxyprogesterone (MPA)-induced breast cancer [<xref rid="B60-vetsci-12-00189" ref-type="bibr">60</xref>] and in the transplantable 4T1 cell model [<xref rid="B160-vetsci-12-00189" ref-type="bibr">160</xref>]. The use of a selective cyclooxygenase-2 (COX-2) inhibitor, etoricoxib, reduced various inflammatory and pro-angiogenic mediators, resulting in decreased tumor growth and increased survival in animals with mammary tumors treated with a diet rich in sugar/fat [<xref rid="B75-vetsci-12-00189" ref-type="bibr">75</xref>].</p><p>Tumor inhibition by ketoprofen, a nonsteroidal anti-inflammatory drug, was also observed in the Ehrlich solid tumor model; however, no differences were found in the percentage of inflammation, hemorrhage, or tumor necrosis [<xref rid="B161-vetsci-12-00189" ref-type="bibr">161</xref>]. In humans, 93.5% of the breast cancer patients in our study exhibited high body fat and deficiencies in calcium and vitamin A, B6, and B12 intake [<xref rid="B162-vetsci-12-00189" ref-type="bibr">162</xref>]. Among human breast cancer patients, obesity was also associated with a higher risk of cancer recurrence and decreased survival [<xref rid="B163-vetsci-12-00189" ref-type="bibr">163</xref>].</p><p>Beyond conventional drug delivery methods, nanosystem-based therapies have been investigated to achieve more effective treatments with fewer side effects. For instance, a nanostructured lipid carrier (NLC) loaded with doxorubicin (DOX) demonstrated superior tumor reduction in the 4T1 breast cancer model compared to liposomes or free DOX [<xref rid="B164-vetsci-12-00189" ref-type="bibr">164</xref>]. Moreover, combining NLC-DOX with docosahexaenoic acid (DHA) proved effective not only for treatment but also for diagnostic and monitoring applications, broadening its potential utility in breast cancer therapy [<xref rid="B165-vetsci-12-00189" ref-type="bibr">165</xref>]. Similarly, formulations such as liposomes loaded with DOX and alpha-tocopheryl succinate, pH-sensitive liposomes containing ursolic acid, and liposomes co-encapsulating paclitaxel and doxorubicin enhanced antitumor efficacy while simultaneously reducing systemic toxicity [<xref rid="B166-vetsci-12-00189" ref-type="bibr">166</xref>,<xref rid="B167-vetsci-12-00189" ref-type="bibr">167</xref>,<xref rid="B168-vetsci-12-00189" ref-type="bibr">168</xref>].</p><p>Between 2020 and 2024, several innovative nanosystem platforms were developed, including exosome-fused liposomes loaded with doxorubicin (ExoSpHL-DOX), pH-sensitive PEGylated liposomes carrying cisplatin or doxorubicin (pHPL-CIS/DOX), and hybrid PEGylated pH-sensitive liposomes combined with extracellular vesicles derived from human breast cancer cells (MDA-MB-231) [<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>,<xref rid="B167-vetsci-12-00189" ref-type="bibr">167</xref>,<xref rid="B169-vetsci-12-00189" ref-type="bibr">169</xref>].</p><p>In studies using ExoSpHL-DOX, 4T1 tumor-bearing mice demonstrated increased cellular uptake of the formulation by 4T1 cells, significant tumor growth reduction, and decreased mortality rates. Importantly, this platform also exhibited substantially reduced toxicity to the liver and heart, revealing its potential for breast cancer therapy [<xref rid="B169-vetsci-12-00189" ref-type="bibr">169</xref>]. Furthermore, non-PEGylated liposomes were shown to achieve superior tumor targeting compared to their PEGylated counterparts, providing critical insights into the optimization of nanosystem design for enhanced therapeutic efficacy [<xref rid="B59-vetsci-12-00189" ref-type="bibr">59</xref>,<xref rid="B167-vetsci-12-00189" ref-type="bibr">167</xref>]. Finally, the hybrid pegylated pH-sensitive liposome-extracellular vesicle derived from the MDA-MB-231 cell line showed cytotoxicity against human breast cancer cell lines with different molecular subtypes, enhanced anti-migration properties, and exhibited a similar cellular uptake to the free DOX treatment. Yet, preliminary acute toxicity assessments using BALB/c female mice indicated a median lethal dose of 15&#x02013;17.5 mg/kg, with no evidence of splenic, liver, heart, bone marrow, or renal cytotoxicity at a dose of 15 mg/kg [<xref rid="B170-vetsci-12-00189" ref-type="bibr">170</xref>].</p></sec><sec id="sec7-vetsci-12-00189"><title>7. Treatment (Canine and Feline)</title><p>Despite the absence of robust prospective clinical trial data allowing us to confidently determine the best treatment strategies for canine and feline mammary gland neoplasms [<xref rid="B171-vetsci-12-00189" ref-type="bibr">171</xref>], our group has made &#x0201c;significant&#x0201d; contributions to the field with multiple studies that evaluate surgical and systemic therapies.</p><p>In addition to enabling histopathological assessment, surgical excision increases overall survival and quality of life and may be curative in non-metastatic cases [<xref rid="B55-vetsci-12-00189" ref-type="bibr">55</xref>]. Adjuvant therapies are commonly recommended for high-risk mammary neoplasms, i.e., large tumors, advanced clinical staging, aggressive histology, and histological grade [<xref rid="B54-vetsci-12-00189" ref-type="bibr">54</xref>,<xref rid="B171-vetsci-12-00189" ref-type="bibr">171</xref>]. Indeed, Nunes et al. (2019) [<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>] demonstrated that carcinosarcomas clearly benefited from the addition of adjuvant therapies (chemotherapy with or without anti-angiogenic agents) following surgical excision, resulting in a more than three-fold increase in median overall survival. Importantly, the benefit of adjuvant therapies was not shown in carcinomas in mixed tumors, a tumor type associated with a superior prognosis [<xref rid="B52-vetsci-12-00189" ref-type="bibr">52</xref>].</p><p>In our evaluation of chemotherapy and cyclooxygenase (COX) inhibitors as adjuncts to surgery, we found a low COX-2 score in 41% and high COX-2 score in 59% of the evaluated cases. An increased COX-2 score was associated with decreased overall survival. Importantly, adjuvant chemotherapy with carboplatin, with or without COX-2 inhibitors (piroxicam or firocoxib), significantly improved overall survival compared to surgery alone, with minimal adverse events [<xref rid="B172-vetsci-12-00189" ref-type="bibr">172</xref>].</p><p>Then, we evaluated the addition of anti-angiogenic and immunomodulatory therapies to surgical resection and carboplatin-based chemotherapy [<xref rid="B157-vetsci-12-00189" ref-type="bibr">157</xref>]. The addition of thalidomide or metronomic chemotherapy with cyclophosphamide and firocoxib more than doubled the median overall survival in dogs with distant metastases compared to surgery alone or surgery with carboplatin. Remarkably, median overall survival exceeded one year in these advanced-stage cases, with many patients experiencing slower disease progression and, in some cases, regression of distant metastatic lesions, leading to markedly improved clinical outcomes.</p><p>Thalidomide&#x02019;s safety profile was also evaluated in dogs with advanced-clinical-stage mammary gland neoplasms. The drug was well-tolerated, with minor alterations in complete blood count and serum biochemistry. While 50% of patients experienced increased somnolence at a dose of 20 mg/kg, less than 10% of pet owners reported a negative impact on the animal&#x02019;s quality of life [<xref rid="B57-vetsci-12-00189" ref-type="bibr">57</xref>].</p><p>Collectively, our findings strongly support the use of adjuvant therapies for high-risk canine mammary gland neoplasms. These treatments were well-tolerated and resulted in significant survival benefits in patients with advanced clinical staging and aggressive histological features.</p><p>It is important to continue to explore additional treatment protocols, dissecting therapeutic response by high-risk features.</p><p>Finally, we conducted a retrospective study on the impact of adjuvant chemotherapy with carboplatin in feline mammary gland neoplasms with an advanced clinical stage and high histological grade. Although carboplatin was well-tolerated, no significant survival benefit was observed [<xref rid="B173-vetsci-12-00189" ref-type="bibr">173</xref>]. Further studies are needed to identify effective adjuvant treatments for feline mammary neoplasms.</p><p>There are ongoing controversies regarding the treatment of mammary neoplasms in female dogs and cats. Chemotherapy protocols remain inadequately established due to the need for standardization and uniformity in staging criteria and, most importantly, histopathological diagnosis. This highlights the importance of adopting the same diagnostic criteria used in human oncology to achieve translational objectives [<xref rid="B34-vetsci-12-00189" ref-type="bibr">34</xref>]. Moreover, the similarities between human and canine neoplasms extend to responses to conventional therapies, the development of treatment resistance, tumor dissemination during metastasis, and recurrence patterns. These interspecies similarities have enabled the application of targeted therapy knowledge from human oncology to animals with comparable molecular profiles. Despite the limited data and understanding of animal tumors, the advancement of precision medicine in veterinary oncology has been facilitated by these characteristics shared among the species investigated [<xref rid="B174-vetsci-12-00189" ref-type="bibr">174</xref>].</p></sec><sec sec-type="conclusions" id="sec8-vetsci-12-00189"><title>8. Conclusions and Future Directions</title><p>In vivo breast cancer models, whether experimental or spontaneous, have demonstrated broad utility in various contexts and will continue to play a pivotal role in understanding tumor progression mechanisms, therapeutic responses, and treatment resistance. Over the past decades, this field has advanced significantly, and it is poised to evolve further with the development of new tools that expand the available arsenal for investigating unresolved scientific questions. However, it is imperative for researchers to consider the inherent limitations of each model and carefully select the one that best represents the specific biological processes under study, aligning with the unique objectives of the research.</p><p>Furthermore, fostering greater interdisciplinary collaboration and translational research among the fields of veterinary oncology, medical oncology, and other cancer research areas is crucial. This includes engaging professionals such as biomedical scientists, biologists, pharmacists, nutritionists, and nurses, promoting the active contribution of each field. Mammary cancer remains the leading cause of cancer-related mortality among women worldwide and also exhibits a high prevalence in female dogs and cats. So far, the group&#x02019;s study focus has been on comparative morphological aspects of spontaneous mammary neoplasms and prognostic and predictive factors; however, genetic studies may in the future complement the data obtained to date.</p><p>It is important to recognize that there is no single ideal experimental model. Breast cancer is highly heterogeneous in its histopathology, growth factor dependence, activation or inactivation of specific genes, clinical progression, and treatment response. Thus, a detailed understanding of the characteristics and limitations of the selected model is essential to maximize its scientific relevance.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was funded by the National Council for Scientific and Technological Development (CNPq), the Minas Gerais Research Foundation&#x02013;FAPEMIG, the Minas Gerais Network for Translational Research in Immunobiologicals and Biopharmaceuticals in Cancer (REMITRIBIC, RED-00031-21), and the Coordination for Personal Improvement of Higher Education (CAPES), Brazil.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, G.D.C.; Writing&#x02014;Original Draft Preparation, G.D.C., K.Y.R.N., M.S., M.P.d.R., M.A.N.R., C.B.d.C., E.F., A.C.B.R., D.C.d.R., K.A.D. and A.E.-L.; Writing&#x02014;Review and Editing, G.D.C., K.Y.R.N., M.S. and M.P.d.R.; Supervision, G.D.C.; Figure preparation&#x02014;M.S. and M.A.N.R. All authors have read and agreed to the published version of the manuscript. </p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00189"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holen</surname><given-names>I.</given-names></name>
<name><surname>Speirs</surname><given-names>V.</given-names></name>
<name><surname>Morrissey</surname><given-names>B.</given-names></name>
<name><surname>Blyth</surname><given-names>K.</given-names></name>
</person-group><article-title>In vivo models in breast cancer research: Progress, challenges and future directions</article-title><source>Dis. Model. Mech</source><year>2017</year><volume>10</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1242/dmm.028274</pub-id><pub-id pub-id-type="pmid">28381598</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00189"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>K.U.</given-names></name>
</person-group><article-title>Models of breast cancer: <italic toggle="yes">Quo vadis</italic>, animal modeling?</article-title><source>Breast Cancer Res.</source><year>2003</year><volume>6</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1186/bcr723</pub-id><pub-id pub-id-type="pmid">14680483</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00189"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>J.D.</given-names></name>
<name><surname>Breen</surname><given-names>M.</given-names></name>
</person-group><article-title>Comparative oncology: What dogs and other species can teach us about humans with cancer</article-title><source>Philos. Trans. R. Soc. B</source><year>2015</year><volume>370</volume><fpage>20140231</fpage><pub-id pub-id-type="doi">10.1098/rstb.2014.0231</pub-id><pub-id pub-id-type="pmid">26056372</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00189"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paoloni</surname><given-names>M.</given-names></name>
<name><surname>Khanna</surname><given-names>C.</given-names></name>
</person-group><article-title>Translation of new cancer treatments from pet dogs to humans</article-title><source>Nat. Rev. Cancer</source><year>2008</year><volume>8</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1038/nrc2273</pub-id><pub-id pub-id-type="pmid">18202698</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00189"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>J.</given-names></name>
</person-group><article-title>Comparative oncology: Overcoming human cancer through companion animal studies</article-title><source>Exp. Mol. Med.</source><year>2023</year><volume>55</volume><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-00977-3</pub-id><pub-id pub-id-type="pmid">37009802</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00189"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira-Lopes</surname><given-names>A.F.</given-names></name>
<name><surname>Amorim</surname><given-names>I.</given-names></name>
<name><surname>Lopes</surname><given-names>C.</given-names></name>
<name><surname>Santos</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer</article-title><source>Vet. Comp. Oncol.</source><year>2024</year><volume>22</volume><fpage>340</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1111/vco.12996</pub-id><pub-id pub-id-type="pmid">39011576</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00189"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>J.Y.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Kang</surname><given-names>M.S.</given-names></name>
<name><surname>Lee</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Canine as a comparative and translational model for human mammary tumor</article-title><source>J. Breast Cancer</source><year>2023</year><volume>26</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.4048/jbc.2023.26.e4</pub-id><pub-id pub-id-type="pmid">36762784</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00189"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelmegeed</surname><given-names>S.M.</given-names></name>
<name><surname>Mohammed</surname><given-names>S.</given-names></name>
</person-group><article-title>Canine mammary tumors as a model for human disease</article-title><source>Oncol. Lett.</source><year>2018</year><volume>15</volume><fpage>8195</fpage><lpage>8205</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8411</pub-id><pub-id pub-id-type="pmid">29928319</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00189"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cannon</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Cats, cancer and comparative oncology</article-title><source>Vet. Sci.</source><year>2015</year><volume>2</volume><fpage>111</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.3390/vetsci2030111</pub-id><pub-id pub-id-type="pmid">29061935</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00189"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.-M.</given-names></name>
<name><surname>Yang</surname><given-names>I.-S.</given-names></name>
<name><surname>Seung</surname><given-names>B.J.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Kang</surname><given-names>K.</given-names></name>
<name><surname>Park</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Cross-species oncogenic signatures of breast cancer in canine mammary tumors</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3616</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17458-0</pub-id><pub-id pub-id-type="pmid">32680987</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00189"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinard</surname><given-names>C.J.</given-names></name>
<name><surname>Antonescu</surname><given-names>C.</given-names></name>
<name><surname>Griffey</surname><given-names>C.</given-names></name>
<name><surname>McNeal</surname><given-names>M.</given-names></name>
<name><surname>Gill</surname><given-names>H.</given-names></name>
</person-group><article-title>Comparative evaluation of tumor-infiltrating lymphocytes in companion animals: Immuno-oncology as a relevant translational model for cancer therapy</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>5008</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14205008</pub-id><pub-id pub-id-type="pmid">36291791</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00189"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adega</surname><given-names>F.</given-names></name>
<name><surname>Borges</surname><given-names>A.</given-names></name>
<name><surname>Chaves</surname><given-names>R.</given-names></name>
</person-group><article-title>Cat mammary tumors: Genetic models for the human counterpart</article-title><source>Vet. Sci.</source><year>2016</year><volume>3</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci3030017</pub-id><pub-id pub-id-type="pmid">29056725</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00189"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
<name><surname>Munday</surname><given-names>J.S.</given-names></name>
<name><surname>Miller</surname><given-names>M.A.</given-names></name>
<name><surname>Paoloni</surname><given-names>M.C.</given-names></name>
<name><surname>Khanna</surname><given-names>C.</given-names></name>
</person-group><article-title>Feline mammary tumours in comparative oncology</article-title><source>J. Dairy Res.</source><year>2005</year><volume>72</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1017/S0022029905001263</pub-id><pub-id pub-id-type="pmid">16180727</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00189"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>F.R.</given-names></name>
<name><surname>Moreira</surname><given-names>I.S.</given-names></name>
<name><surname>Dariva</surname><given-names>A.A.</given-names></name>
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Abreu</surname><given-names>C.C.</given-names></name>
<name><surname>Balabram</surname><given-names>D.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Epidemiologic and Clinicopathological Characterization of Feline Mammary Lesions</article-title><source>Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>549</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci11110549</pub-id><pub-id pub-id-type="pmid">39591323</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00189"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>R.</given-names></name>
</person-group><article-title>Comparison of age, sex, and incidence rates in human and canine breast cancer</article-title><source>Cancer</source><year>1970</year><volume>26</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197008)26:2&#x0003c;419::AID-CNCR2820260225&#x0003e;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">5465470</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00189"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Teixeira</surname><given-names>S.V.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Epidemiological, clinical and pathological evaluation of overall survival in canines with mammary neoplasms</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2018</year><volume>70</volume><fpage>1714</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-10217</pub-id></element-citation></ref><ref id="B17-vetsci-12-00189"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strandberg</surname><given-names>J.D.</given-names></name>
<name><surname>Goodman</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Animal model of human disease: Canine mammary neoplasia</article-title><source>Am. J. Pathol.</source><year>1974</year><volume>75</volume><fpage>225</fpage><pub-id pub-id-type="pmid">4825616</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00189"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarkar</surname><given-names>S.</given-names></name>
<name><surname>Lahiri</surname><given-names>A.</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name>
<name><surname>Das</surname><given-names>S.</given-names></name>
<name><surname>Chakraborty</surname><given-names>T.</given-names></name>
</person-group><article-title>Benign and malignant lesions of the breast: Clinico-pathological perspective from a government teaching hospital in West Bengal, India</article-title><source>Int. Surg. J.</source><year>2018</year><volume>5</volume><fpage>3460</fpage><pub-id pub-id-type="doi">10.18203/2349-2902.isj20184609</pub-id></element-citation></ref><ref id="B19-vetsci-12-00189"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usman</surname><given-names>A.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Lakhanna</surname><given-names>N.K.</given-names></name>
<name><surname>Zafar</surname><given-names>H.</given-names></name>
</person-group><article-title>Frequency of benign and malignant breast lesions: A histopathological analysis</article-title><source>Isra Med. J.</source><year>2016</year><volume>8</volume><fpage>138</fpage><lpage>140</lpage></element-citation></ref><ref id="B20-vetsci-12-00189"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>L.C.S.</given-names></name>
</person-group><article-title>Perspectivas futuras do tratamento do c&#x000e2;ncer de mama</article-title><source>Patologia Mam&#x000e1;ria Canina e Felina: Do Diagn&#x000f3;stico ao Tratamento</source><edition>2nd ed.</edition><person-group person-group-type="editor">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><publisher-name>MedVet</publisher-name><publisher-loc>S&#x000e3;o Paulo, Brazil</publisher-loc><year>2023</year><fpage>431</fpage><lpage>442</lpage></element-citation></ref><ref id="B21-vetsci-12-00189"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO Classification of Tumours Editorial Board</collab>
</person-group><source>Breast Tumours</source><edition>5th ed.</edition><publisher-name>International Agency for Research on Cancer</publisher-name><publisher-loc>Lyon, France</publisher-loc><year>2019</year><fpage>2</fpage><lpage>319</lpage></element-citation></ref><ref id="B22-vetsci-12-00189"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prier</surname><given-names>J.E.</given-names></name>
<name><surname>Brodey</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Canine neoplasia: A prototype for human cancer study</article-title><source>Bull. World Health Organ.</source><year>1963</year><volume>29</volume><fpage>331</fpage><pub-id pub-id-type="pmid">14058226</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00189"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Gobbi</surname><given-names>H.</given-names></name>
<name><surname>Saraiva</surname><given-names>B.S.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Columnar cell lesions of the canine mammary gland: Pathological features and immunophenotypic analysis</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-10-61</pub-id><pub-id pub-id-type="pmid">20178635</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00189"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Gobbi</surname><given-names>H.</given-names></name>
<name><surname>Saraiva</surname><given-names>B.S.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Histological and immunohistochemical identification of atypical ductal mammary hyperplasia as a preneoplastic marker in dogs</article-title><source>Vet. Pathol.</source><year>2012</year><volume>49</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1177/0300985810396105</pub-id><pub-id pub-id-type="pmid">21282668</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00189"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strickland</surname><given-names>S.</given-names></name>
<name><surname>Turashvili</surname><given-names>G.</given-names></name>
</person-group><article-title>Are columnar cell lesions the earliest non-obligate precursor in the low-grade breast neoplasia pathway?</article-title><source>Curr. Oncol.</source><year>2022</year><volume>29</volume><fpage>5664</fpage><lpage>5681</lpage><pub-id pub-id-type="doi">10.3390/curroncol29080447</pub-id><pub-id pub-id-type="pmid">36005185</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00189"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boer</surname><given-names>M.</given-names></name>
<name><surname>Verschuur-Maes</surname><given-names>A.H.J.</given-names></name>
<name><surname>Buerger</surname><given-names>H.</given-names></name>
<name><surname>Moelans</surname><given-names>C.B.</given-names></name>
<name><surname>Steenkamer</surname><given-names>M.</given-names></name>
<name><surname>Savola</surname><given-names>S.</given-names></name>
<name><surname>Diest</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Role of columnar cell lesions in breast carcinogenesis: Analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification</article-title><source>Mod. Path.</source><year>2018</year><volume>31</volume><fpage>1816</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1038/s41379-018-0099-2</pub-id><pub-id pub-id-type="pmid">29976944</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00189"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Gobbi</surname><given-names>H.</given-names></name>
<name><surname>Gartner</surname><given-names>F.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.C.</given-names></name>
</person-group><article-title>Secretory carcinoma of the canine mammary gland</article-title><source>Vet Pathol.</source><year>1999</year><volume>36</volume><fpage>601</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1354/vp.36-6-601</pub-id><pub-id pub-id-type="pmid">10568441</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00189"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>G&#x000e4;rtner</surname><given-names>F.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.C.</given-names></name>
</person-group><article-title>Pleomorphic lobular carcinoma of the canine mammary gland: Histopathologic and immunohistochemical features</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2002</year><volume>54</volume><fpage>592</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1590/S0102-09352002000600006</pub-id></element-citation></ref><ref id="B29-vetsci-12-00189"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seixas</surname><given-names>F.</given-names></name>
<name><surname>Millanta</surname><given-names>F.</given-names></name>
<name><surname>Poli</surname><given-names>A.</given-names></name>
</person-group><article-title>Mammary invasive micropapillary carcinoma in cats: Clinicopathologic features and nuclear DNA content</article-title><source>Vet. Pathol.</source><year>2007</year><volume>44</volume><fpage>842</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1354/vp.44-6-842</pub-id><pub-id pub-id-type="pmid">18039897</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00189"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Mansour</surname><given-names>M.A.</given-names></name>
<name><surname>Al-Azawi</surname><given-names>A.M.</given-names></name>
<name><surname>Abdu</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Comparative histopathology and immunohistochemistry of human and canine mammary tumors</article-title><source>Open Vet. J.</source><year>2018</year><volume>8</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.4314/ovj.v8i3.3</pub-id><pub-id pub-id-type="pmid">30105215</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00189"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ressel</surname><given-names>L.</given-names></name>
<name><surname>Millanta</surname><given-names>F.</given-names></name>
<name><surname>Poli</surname><given-names>A.</given-names></name>
</person-group><article-title>Canine invasive lobular carcinoma of the mammary gland: Morphological and immunohistochemical characterizations of three cases</article-title><source>J. Comp. Pathol.</source><year>2011</year><volume>144</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2010.08.015</pub-id><pub-id pub-id-type="pmid">20961557</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00189"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Invasive micropapillary carcinoma of the mammary gland in humans and canines: Clinicopathological, immunophenotypical, and survival approaches</article-title><source>Res. Vet. Sci.</source><year>2017</year><volume>115</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2017.04.012</pub-id><pub-id pub-id-type="pmid">28475997</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00189"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>D.</given-names></name>
<name><surname>Reif</surname><given-names>J.</given-names></name>
<name><surname>Brody</surname><given-names>R.S.</given-names></name>
<name><surname>Keiser</surname><given-names>H.</given-names></name>
</person-group><article-title>Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital</article-title><source>Cancer Res.</source><year>1974</year><volume>34</volume><fpage>2859</fpage><lpage>2868</lpage><pub-id pub-id-type="pmid">4529096</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00189"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Jark</surname><given-names>P.C.</given-names></name>
<name><surname>Horta</surname><given-names>R.S.</given-names></name>
<name><surname>Arias</surname><given-names>A.C.</given-names></name>
<name><surname>Tellado</surname><given-names>M.N.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Sueiro</surname><given-names>F.A.</given-names></name>
<name><surname>Reys</surname><given-names>M.P.</given-names></name>
<name><surname>Wronski</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>Consensus on the diagnosis, prognosis, and treatment of canine and feline mammary tumors: Solid arrangement&#x02014;2023</article-title><source>Braz. J. Vet. Pathol.</source><year>2023</year><volume>17</volume><fpage>152</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.24070/bjvp.1983-0246.v17i3p152-163</pub-id></element-citation></ref><ref id="B35-vetsci-12-00189"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>H.D.C.</given-names></name>
<name><surname>Dos Reys</surname><given-names>M.P.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Souza</surname><given-names>F.R.</given-names></name>
<name><surname>Horta</surname><given-names>R.D.S.</given-names></name>
<name><surname>de Sena</surname><given-names>B.V.</given-names></name>
<name><surname>Bindaco</surname><given-names>A.L.S.</given-names></name>
<name><surname>de Pinto</surname><given-names>A.C.J.</given-names></name>
<name><surname>de Souza</surname><given-names>T.D.</given-names></name>
<name><surname>Flecher</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Secretory carcinoma of the canine mammary gland with nodal and bone metastases: Case report</article-title><source>Open Vet. J.</source><year>2022</year><volume>12</volume><fpage>502</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.5455/OVJ.2022.v12.i4.12</pub-id><pub-id pub-id-type="pmid">36118721</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00189"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atula</surname><given-names>T.</given-names></name>
<name><surname>Klemi</surname><given-names>P.J.</given-names></name>
<name><surname>Donath</surname><given-names>K.</given-names></name>
<name><surname>Salo</surname><given-names>S.</given-names></name>
<name><surname>Lehtonen</surname><given-names>E.</given-names></name>
</person-group><article-title>Basal cell adenocarcinoma of the parotid gland: A case report and review of the literature</article-title><source>J. Laryngol. Otol.</source><year>1993</year><volume>107</volume><fpage>862</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1017/S002221510012465X</pub-id><pub-id pub-id-type="pmid">8228612</pub-id>
</element-citation></ref><ref id="B37-vetsci-12-00189"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pohar-Marinsek</surname><given-names>Z.</given-names></name>
<name><surname>Golouh</surname><given-names>R.</given-names></name>
</person-group><article-title>Secretory breast carcinoma in a man diagnosed by fine needle aspiration biopsy</article-title><source>Acta Cytol.</source><year>1994</year><volume>38</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">8191840</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00189"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>A.B.B.</given-names></name>
<name><surname>Rocha</surname><given-names>R.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>First description of basaloid carcinoma of the canine mammary gland: Case report</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2019</year><volume>71</volume><fpage>878</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-10372</pub-id></element-citation></ref><ref id="B39-vetsci-12-00189"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Las Mulas</surname><given-names>J.M.</given-names></name>
<name><surname>Ord&#x000e1;s</surname><given-names>J.</given-names></name>
<name><surname>Mill&#x000e1;n</surname><given-names>M.Y.</given-names></name>
<name><surname>de Los Monteros</surname><given-names>A.E.</given-names></name>
<name><surname>Reymundo</surname><given-names>C.</given-names></name>
</person-group><article-title>Spontaneous basaloid adenomas of the mammary gland in four dogs: Clinicopathologic and immunohistochemical features</article-title><source>Vet. Pathol.</source><year>2002</year><volume>39</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1354/vp.39-6-739</pub-id><pub-id pub-id-type="pmid">12450207</pub-id>
</element-citation></ref><ref id="B40-vetsci-12-00189"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwapien</surname><given-names>R.P.</given-names></name>
<name><surname>Giles</surname><given-names>R.C.</given-names></name>
<name><surname>Geil</surname><given-names>R.G.</given-names></name>
<name><surname>Casey</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Basaloid adenomas of the mammary gland in beagle dogs administered investigational contraceptive steroids</article-title><source>J. Nat. Cancer Inst.</source><year>1997</year><volume>59</volume><fpage>933</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1093/jnci/59.3.933</pub-id><pub-id pub-id-type="pmid">894750</pub-id>
</element-citation></ref><ref id="B41-vetsci-12-00189"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Nunes</surname><given-names>M.M.</given-names></name>
<name><surname>Garcia</surname><given-names>A.P.V.</given-names></name>
<name><surname>De Brot</surname><given-names>M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Neuroendocrine carcinomas of the canine mammary gland: Histopathological and immunohistochemical characteristics</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>7</volume><elocation-id>621714</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2020.621714</pub-id><pub-id pub-id-type="pmid">33469557</pub-id>
</element-citation></ref><ref id="B42-vetsci-12-00189"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldschmidt</surname><given-names>M.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Rasotto</surname><given-names>R.</given-names></name>
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
</person-group><article-title>Classification and grading of canine mammary tumours</article-title><source>Vet Pathol.</source><year>2011</year><volume>48</volume><fpage>117</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1177/0300985810393258</pub-id><pub-id pub-id-type="pmid">21266722</pub-id>
</element-citation></ref><ref id="B43-vetsci-12-00189"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Santis</surname><given-names>G.D.</given-names></name>
<name><surname>Nardi</surname><given-names>A.D.</given-names></name>
<name><surname>Fernandes</surname><given-names>C.G.</given-names></name>
<name><surname>Cogliati</surname><given-names>B.</given-names></name>
<name><surname>Sobral</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Consensus regarding the diagnosis, prognosis, and treatment of canine mammary tumors: Benign mixed tumors, carcinomas in mixed tumors, and carcinosarcomas</article-title><source>Braz. J. Vet. Pathol.</source><year>2017</year><volume>10</volume><fpage>87</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.24070/bjvp.1983-0246.v10i3p87-99</pub-id></element-citation></ref><ref id="B44-vetsci-12-00189"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hampe</surname><given-names>J.F.</given-names></name>
<name><surname>Misdorp</surname><given-names>W.</given-names></name>
</person-group><article-title>Tumours and dysplasias of the mammary gland</article-title><source>Bull. World Health Organ.</source><year>1974</year><volume>50</volume><fpage>111</fpage><pub-id pub-id-type="pmid">4371737</pub-id>
</element-citation></ref><ref id="B45-vetsci-12-00189"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>L.</given-names></name>
<name><surname>Eveson</surname><given-names>J.W.</given-names></name>
<name><surname>Reichart</surname><given-names>P.</given-names></name>
<name><surname>Sidransky</surname><given-names>D.</given-names></name>
</person-group><source>World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours</source><edition>3rd ed.</edition><publisher-name>IARC Press</publisher-name><publisher-loc>Lyon, France</publisher-loc><year>2005</year></element-citation></ref><ref id="B46-vetsci-12-00189"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moulton</surname><given-names>J.E.</given-names></name>
<name><surname>Taylor</surname><given-names>D.O.N.</given-names></name>
<name><surname>Dorn</surname><given-names>C.R.</given-names></name>
<name><surname>Andersen</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Canine Mammary Tumors</article-title><source>Vet. Path.</source><year>1970</year><volume>7</volume><fpage>289</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1177/030098587000700401</pub-id></element-citation></ref><ref id="B47-vetsci-12-00189"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nouraei</surname><given-names>S.A.</given-names></name>
<name><surname>Hope</surname><given-names>K.L.</given-names></name>
<name><surname>Kelly</surname><given-names>C.G.</given-names></name>
<name><surname>McLean</surname><given-names>N.R.</given-names></name>
<name><surname>Soames</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Carcinoma ex benign pleomorphic adenoma of the parotid gland</article-title><source>Plast. Reconstr. Surg.</source><year>2005</year><volume>116</volume><fpage>1206</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1097/01.prs.0000181654.68120.0f</pub-id><pub-id pub-id-type="pmid">16217459</pub-id>
</element-citation></ref><ref id="B48-vetsci-12-00189"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Genelhu</surname><given-names>M.C.</given-names></name>
<name><surname>Cardoso</surname><given-names>S.V.</given-names></name>
<name><surname>Gobbi</surname><given-names>H.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>A comparative study between mixed-type tumours from human salivary and canine mammary glands</article-title><source>BMC Cancer</source><year>2007</year><volume>7</volume><elocation-id>218</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-7-218</pub-id><pub-id pub-id-type="pmid">18045453</pub-id>
</element-citation></ref><ref id="B49-vetsci-12-00189"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>A.F.C.</given-names></name>
<name><surname>Telles</surname><given-names>T.C.</given-names></name>
<name><surname>Ferraz</surname><given-names>V.P.</given-names></name>
<name><surname>Souza-Fagundes</surname><given-names>E.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Carvalho</surname><given-names>A.T.</given-names></name>
<name><surname>Melo</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Effect of Arrabidaea chica extracts on the Ehrlich solid tumor development</article-title><source>Rev. Bras. Farmacogn.</source><year>2012</year><volume>22</volume><fpage>364</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1590/S0102-695X2011005000225</pub-id></element-citation></ref><ref id="B50-vetsci-12-00189"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavalcanti</surname><given-names>M.F.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Fatores progn&#x000f3;sticos no diagn&#x000f3;stico cl&#x000ed;nico e histopatol&#x000f3;gico dos tumores de mama em cadelas: Revis&#x000e3;o</article-title><source>Rev. Cl&#x000ed;nica Veterin&#x000e1;ria</source><year>2006</year><volume>61</volume><fpage>56</fpage><lpage>63</lpage></element-citation></ref><ref id="B51-vetsci-12-00189"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rasotto</surname><given-names>R.</given-names></name>
<name><surname>Berlato</surname><given-names>D.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
</person-group><article-title>Prognostic significance of canine mammary tumor histologic subtypes: An observational cohort study of 229 cases</article-title><source>Vet. Pathol.</source><year>2017</year><volume>54</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1177/0300985817698208</pub-id><pub-id pub-id-type="pmid">28355108</pub-id>
</element-citation></ref><ref id="B52-vetsci-12-00189"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Mixed tumors of the canine mammary glands: Evaluation of prognostic factors, treatment, and overall survival</article-title><source>Vet. Anim. Sci.</source><year>2018</year><volume>7</volume><fpage>100039</fpage><pub-id pub-id-type="doi">10.1016/j.vas.2018.09.003</pub-id><pub-id pub-id-type="pmid">32734062</pub-id>
</element-citation></ref><ref id="B53-vetsci-12-00189"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rauber</surname><given-names>D.</given-names></name>
<name><surname>Gerardi</surname><given-names>D.G.</given-names></name>
<name><surname>Oliveira</surname><given-names>L.O.</given-names></name>
<name><surname>Vieira</surname><given-names>L.C.</given-names></name>
<name><surname>Caprioli</surname><given-names>R.A.</given-names></name>
<name><surname>Pavarini</surname><given-names>S.P.</given-names></name>
<name><surname>Driemeier</surname><given-names>D.</given-names></name>
<name><surname>Sonne</surname><given-names>L.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Rodrigues</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Clinical presentation, histological findings, and prognosis in female dogs with mixed mammary neoplasms</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2023</year><volume>75</volume><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-12640</pub-id></element-citation></ref><ref id="B54-vetsci-12-00189"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Jark</surname><given-names>P.C.</given-names></name>
<name><surname>Gamba</surname><given-names>C.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Lima</surname><given-names>A.E.</given-names></name>
<name><surname>Nardi</surname><given-names>A.B.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Horta</surname><given-names>R.S.</given-names></name>
<name><surname>Firmo</surname><given-names>B.F.</given-names></name>
<name><surname>Sueiro</surname><given-names>F.A.</given-names></name>
<etal/>
</person-group><article-title>Consensus regarding the diagnosis, prognosis and treatment of canine and feline mammary tumors-2019</article-title><source>BJVP</source><year>2020</year><volume>13</volume><fpage>555</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.24070/bjvp.1983-0246.v13i3p555-574</pub-id></element-citation></ref><ref id="B55-vetsci-12-00189"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitzgibbons</surname><given-names>P.L.</given-names></name>
<name><surname>Connolly</surname><given-names>J.L.</given-names></name>
<name><surname>Page</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Updated protocol for the examination of specimens from patients with carcinomas of the breast: A basis for checklists</article-title><source>Arch. Pathol. Lab. Med.</source><year>2000</year><volume>124</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.5858/2000-124-1026-UPFTEO</pub-id><pub-id pub-id-type="pmid">10888779</pub-id>
</element-citation></ref><ref id="B56-vetsci-12-00189"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masood</surname><given-names>S.</given-names></name>
</person-group><article-title>Prognostic/predictive factors in breast cancer</article-title><source>Clin. Lab. Med.</source><year>2005</year><volume>25</volume><fpage>809</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.cll.2005.08.012</pub-id><pub-id pub-id-type="pmid">16308094</pub-id>
</element-citation></ref><ref id="B57-vetsci-12-00189"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<name><surname>Ribeiro</surname><given-names>A.M.</given-names></name>
<name><surname>Machado</surname><given-names>C.J.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms</article-title><source>J. Feline Med. Surg.</source><year>2016</year><volume>18</volume><fpage>1003</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1177/1098612X15610367</pub-id><pub-id pub-id-type="pmid">26460079</pub-id>
</element-citation></ref><ref id="B58-vetsci-12-00189"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elston</surname><given-names>C.W.</given-names></name>
<name><surname>Ellis</surname><given-names>I.O.</given-names></name>
<name><surname>Pinder</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Pathological prognostic factors in breast cancer</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>1999</year><volume>31</volume><fpage>209</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S1040-8428(99)00034-7</pub-id><pub-id pub-id-type="pmid">10532196</pub-id>
</element-citation></ref><ref id="B59-vetsci-12-00189"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>de Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>The prognostic significance of immunophenotypes in canine malignant mammary tumors</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2022</year><volume>74</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-12273</pub-id></element-citation></ref><ref id="B60-vetsci-12-00189"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tarighati</surname><given-names>E.</given-names></name>
<name><surname>Keivan</surname><given-names>H.</given-names></name>
<name><surname>Mahani</surname><given-names>H.</given-names></name>
</person-group><article-title>A review of prognostic and predictive biomarkers in breast cancer</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>23</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10238-021-00781-1</pub-id><pub-id pub-id-type="pmid">35031885</pub-id>
</element-citation></ref><ref id="B61-vetsci-12-00189"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00141;ukasiewicz</surname><given-names>S.</given-names></name>
<name><surname>Czeczelewski</surname><given-names>M.</given-names></name>
<name><surname>Forma</surname><given-names>A.</given-names></name>
<name><surname>Baj</surname><given-names>J.</given-names></name>
<name><surname>Sitarz</surname><given-names>R.</given-names></name>
<name><surname>Stanis&#x00142;awek</surname><given-names>A.</given-names></name>
</person-group><article-title>Breast cancer&#x02014;Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies&#x02014;An updated review</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>4287</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13174287</pub-id><pub-id pub-id-type="pmid">34503097</pub-id>
</element-citation></ref><ref id="B62-vetsci-12-00189"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gnant</surname><given-names>M.</given-names></name>
<name><surname>Harbeck</surname><given-names>N.</given-names></name>
<name><surname>Thomssen</surname><given-names>C.</given-names></name>
</person-group><article-title>St. Gallen/Vienna 2017: A brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment</article-title><source>Breast Care</source><year>2017</year><volume>12</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1159/000475698</pub-id><pub-id pub-id-type="pmid">28559767</pub-id>
</element-citation></ref><ref id="B63-vetsci-12-00189"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giuliano</surname><given-names>A.E.</given-names></name>
<name><surname>Edge</surname><given-names>S.B.</given-names></name>
<name><surname>Hortobagyi</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Eighth edition of the AJCC cancer staging manual: Breast cancer</article-title><source>Ann. Surg. Oncol.</source><year>2018</year><volume>25</volume><fpage>1783</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1245/s10434-018-6486-6</pub-id><pub-id pub-id-type="pmid">29671136</pub-id>
</element-citation></ref><ref id="B64-vetsci-12-00189"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
<name><surname>Rasotto</surname><given-names>R.</given-names></name>
<name><surname>Caliari</surname><given-names>D.</given-names></name>
<name><surname>Mainenti</surname><given-names>M.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
<name><surname>Poli</surname><given-names>A.</given-names></name>
<name><surname>Kiupel</surname><given-names>M.</given-names></name>
</person-group><article-title>Prognostic evaluation of feline mammary carcinomas: A review of the literature</article-title><source>Vet. Pathol.</source><year>2015</year><volume>52</volume><fpage>46</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/0300985814528221</pub-id><pub-id pub-id-type="pmid">24741029</pub-id>
</element-citation></ref><ref id="B65-vetsci-12-00189"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bloom</surname><given-names>H.J.G.</given-names></name>
<name><surname>Richardson</surname><given-names>W.W.</given-names></name>
</person-group><article-title>Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years</article-title><source>Br. J. Cancer</source><year>1957</year><volume>11</volume><fpage>359</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/bjc.1957.43</pub-id><pub-id pub-id-type="pmid">13499785</pub-id>
</element-citation></ref><ref id="B66-vetsci-12-00189"><label>66.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Elston</surname><given-names>C.W.</given-names></name>
<name><surname>Ellis</surname><given-names>I.O.</given-names></name>
</person-group><article-title>Assessment of histological grade</article-title><source>Systemic Pathology. The Breast</source><edition>3rd ed.</edition><person-group person-group-type="editor">
<name><surname>Elston</surname><given-names>C.W.</given-names></name>
<name><surname>Ellis</surname><given-names>I.O.</given-names></name>
</person-group><publisher-name>Churchill Livingstone</publisher-name><publisher-loc>London, UK</publisher-loc><year>1998</year><fpage>365</fpage><lpage>384</lpage></element-citation></ref><ref id="B67-vetsci-12-00189"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elston</surname><given-names>C.W.</given-names></name>
<name><surname>Ellis</surname><given-names>I.O.</given-names></name>
</person-group><article-title>Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up</article-title><source>Histopathology</source><year>1991</year><volume>19</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.1991.tb00229.x</pub-id><pub-id pub-id-type="pmid">1757079</pub-id>
</element-citation></ref><ref id="B68-vetsci-12-00189"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ara&#x000fa;jo</surname><given-names>M.R.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Brodey</surname><given-names>R.S.</given-names></name>
<name><surname>Fialho Lig&#x000f3;rio</surname><given-names>S.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival</article-title><source>Res. Vet. Sci.</source><year>2016</year><volume>106</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2016.03.020</pub-id><pub-id pub-id-type="pmid">27234549</pub-id>
</element-citation></ref><ref id="B69-vetsci-12-00189"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dutra</surname><given-names>A.P.</given-names></name>
<name><surname>Azevedo J&#x000fa;nior</surname><given-names>G.M.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Assessment of cell proliferation and prognostic factors in canine mammary gland tumors</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2008</year><volume>60</volume><fpage>1403</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1590/S0102-09352008000600015</pub-id></element-citation></ref><ref id="B70-vetsci-12-00189"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karayannopoulou</surname><given-names>M.</given-names></name>
<name><surname>Papadopoulos</surname><given-names>O.</given-names></name>
<name><surname>Hounta</surname><given-names>A.</given-names></name>
<name><surname>Antoniou</surname><given-names>S.</given-names></name>
<name><surname>Koutinas</surname><given-names>A.</given-names></name>
</person-group><article-title>Histological grading and prognosis in dogs with mammary carcinomas: Application of a human grading method</article-title><source>J. Comp. Pathol.</source><year>2005</year><volume>133</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2005.05.003</pub-id><pub-id pub-id-type="pmid">16202421</pub-id>
</element-citation></ref><ref id="B71-vetsci-12-00189"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canadas</surname><given-names>A.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>P.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>M.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>I.</given-names></name>
<name><surname>Esparza</surname><given-names>V.</given-names></name>
<name><surname>Ruiz</surname><given-names>R.</given-names></name>
<name><surname>Montes</surname><given-names>J.</given-names></name>
<name><surname>G&#x000f3;mez</surname><given-names>I.</given-names></name>
</person-group><article-title>Canine mammary tumors: Comparison of classification and grading methods in a survival study</article-title><source>Vet. Pathol.</source><year>2019</year><volume>56</volume><fpage>208</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1177/0300985818806968</pub-id><pub-id pub-id-type="pmid">30381007</pub-id>
</element-citation></ref><ref id="B72-vetsci-12-00189"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castagnaro</surname><given-names>M.</given-names></name>
<name><surname>D&#x02019;Angelo</surname><given-names>M.</given-names></name>
<name><surname>Santucci</surname><given-names>R.</given-names></name>
<name><surname>Guscetti</surname><given-names>F.</given-names></name>
<name><surname>Callea</surname><given-names>F.T.</given-names></name>
</person-group><article-title>Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas</article-title><source>J. Comp. Pathol.</source><year>1998</year><volume>119</volume><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/S0021-9975(98)80049-2</pub-id><pub-id pub-id-type="pmid">9807728</pub-id>
</element-citation></ref><ref id="B73-vetsci-12-00189"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fidler</surname><given-names>I.J.</given-names></name>
<name><surname>Brodey</surname><given-names>R.S.</given-names></name>
</person-group><article-title>The biological behavior of canine mammary neoplasms</article-title><source>J. Am. Vet. Med. Assoc.</source><year>1967</year><volume>151</volume><fpage>1312</fpage><lpage>1318</lpage></element-citation></ref><ref id="B74-vetsci-12-00189"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ara&#x000fa;jo</surname><given-names>M.R.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Brodey</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Quantitation of the regional lymph node metastatic burden and prognosis in malignant mammary tumors of dogs</article-title><source>J. Vet. Intern. Med.</source><year>2015</year><volume>29</volume><fpage>1360</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1111/jvim.13576</pub-id><pub-id pub-id-type="pmid">26130166</pub-id>
</element-citation></ref><ref id="B75-vetsci-12-00189"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gon&#x000e7;alves</surname><given-names>A.D.B.B.</given-names></name>
<name><surname>Silva</surname><given-names>L.R.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Extracapsular extension and tumor implants in lymph nodes with canine mammary carcinoma metastasdutris: Study of the impact on survival</article-title><source>Res. Vet. Sci.</source><year>2021</year><volume>139</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2021.07.010</pub-id><pub-id pub-id-type="pmid">34265511</pub-id>
</element-citation></ref><ref id="B76-vetsci-12-00189"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonacho</surname><given-names>T.R.F.L.J.</given-names></name>
<name><surname>Rodrigues</surname><given-names>F.</given-names></name>
<name><surname>Liberal</surname><given-names>J.</given-names></name>
</person-group><article-title>Immunohistochemistry for diagnosis and prognosis of breast cancer: A review</article-title><source>Biotech. Histochem.</source><year>2020</year><volume>95</volume><fpage>71</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1080/10520295.2019.1651901</pub-id><pub-id pub-id-type="pmid">31502889</pub-id>
</element-citation></ref><ref id="B77-vetsci-12-00189"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esteva</surname><given-names>F.J.</given-names></name>
<name><surname>Hortobagyi</surname><given-names>G.N.</given-names></name>
</person-group><article-title>Prognostic molecular markers in early breast cancer</article-title><source>Breast Cancer Res.</source><year>2004</year><volume>6</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/bcr777</pub-id><pub-id pub-id-type="pmid">15084231</pub-id>
</element-citation></ref><ref id="B78-vetsci-12-00189"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>K.</given-names></name>
<name><surname>Fry</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Novel molecular markers for breast cancer</article-title><source>Biomark. Cancer</source><year>2016</year><volume>8</volume><fpage>BIC-S38394</fpage><pub-id pub-id-type="doi">10.4137/BIC.S38394</pub-id></element-citation></ref><ref id="B79-vetsci-12-00189"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banin Hirata</surname><given-names>B.K.</given-names></name>
<name><surname>Almeida</surname><given-names>D.R.</given-names></name>
<name><surname>Santos</surname><given-names>R.A.</given-names></name>
<name><surname>Cunha</surname><given-names>I.W.</given-names></name>
</person-group><article-title>Molecular markers for breast cancer: Prediction on tumor behavior</article-title><source>Dis. Markers</source><year>2014</year><volume>2014</volume><fpage>513158</fpage><pub-id pub-id-type="doi">10.1155/2014/513158</pub-id><pub-id pub-id-type="pmid">24591761</pub-id>
</element-citation></ref><ref id="B80-vetsci-12-00189"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kretschmer</surname><given-names>C.</given-names></name>
<name><surname>Stein</surname><given-names>R.</given-names></name>
<name><surname>Riedel</surname><given-names>T.</given-names></name>
<name><surname>Fendler</surname><given-names>W.</given-names></name>
<name><surname>Cussenot</surname><given-names>O.</given-names></name>
<name><surname>Schmid</surname><given-names>M.</given-names></name>
<name><surname>Schmitt</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of early molecular markers for breast cancer</article-title><source>Mol. Cancer</source><year>2011</year><volume>10</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-10-15</pub-id><pub-id pub-id-type="pmid">21314937</pub-id>
</element-citation></ref><ref id="B81-vetsci-12-00189"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duffy</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Predictive markers in breast and other cancers: A review</article-title><source>Clin. Chem.</source><year>2005</year><volume>51</volume><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2004.046227</pub-id><pub-id pub-id-type="pmid">15637130</pub-id>
</element-citation></ref><ref id="B82-vetsci-12-00189"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>J.E.</given-names></name>
<name><surname>Goetz</surname><given-names>C.</given-names></name>
<name><surname>Bender</surname><given-names>R.</given-names></name>
<name><surname>Walker</surname><given-names>M.</given-names></name>
<name><surname>Colburn</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Labaer</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular markers for breast cancer diagnosis, prognosis, and targeted therapy</article-title><source>J. Surg. Oncol.</source><year>2015</year><volume>111</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/jso.23732</pub-id><pub-id pub-id-type="pmid">25091830</pub-id>
</element-citation></ref><ref id="B83-vetsci-12-00189"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>N.Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Research progress of good markers for canine mammary carcinoma</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>10617</fpage><lpage>10625</lpage><pub-id pub-id-type="doi">10.1007/s11033-023-08863-x</pub-id><pub-id pub-id-type="pmid">37943402</pub-id>
</element-citation></ref><ref id="B84-vetsci-12-00189"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaszak</surname><given-names>I.</given-names></name>
<name><surname>Sokol</surname><given-names>E.</given-names></name>
<name><surname>Baranowski</surname><given-names>M.</given-names></name>
<name><surname>Malkowski</surname><given-names>P.</given-names></name>
<name><surname>Nowicki</surname><given-names>M.</given-names></name>
<name><surname>Kawecka</surname><given-names>A.</given-names></name>
</person-group><article-title>Current biomarkers of canine mammary tumors</article-title><source>Acta Vet. Scand.</source><year>2018</year><volume>60</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s13028-018-0417-1</pub-id><pub-id pub-id-type="pmid">30373614</pub-id>
</element-citation></ref><ref id="B85-vetsci-12-00189"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gherman</surname><given-names>L.-M.</given-names></name>
<name><surname>Negru</surname><given-names>A.</given-names></name>
<name><surname>Olariu</surname><given-names>M.</given-names></name>
<name><surname>Ion</surname><given-names>L.</given-names></name>
</person-group><article-title>Molecular markers in canine mammary tumors</article-title><source>Acta Vet.</source><year>2024</year><volume>74</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.2478/acve-2024-0012</pub-id></element-citation></ref><ref id="B86-vetsci-12-00189"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Ruiz</surname><given-names>R.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>P.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>E.</given-names></name>
<name><surname>Mart&#x000ed;n de las Mulas</surname><given-names>J.</given-names></name>
<name><surname>Calvo</surname><given-names>S.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>I.</given-names></name>
</person-group><article-title>Canine mammary tumors: A review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry</article-title><source>Vet. Pathol.</source><year>2014</year><volume>51</volume><fpage>127</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1177/0300985813509388</pub-id><pub-id pub-id-type="pmid">24227007</pub-id>
</element-citation></ref><ref id="B87-vetsci-12-00189"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>K.</given-names></name>
<name><surname>Dobson</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Prognostic histopathological and molecular markers in feline mammary neoplasia</article-title><source>Vet. J.</source><year>2012</year><volume>194</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2012.05.008</pub-id><pub-id pub-id-type="pmid">22841451</pub-id>
</element-citation></ref><ref id="B88-vetsci-12-00189"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aupperle-Lellbach</surname><given-names>H.</given-names></name>
<name><surname>Balogh</surname><given-names>O.</given-names></name>
<name><surname>Freise</surname><given-names>F.</given-names></name>
<name><surname>M&#x000f6;hlenbrink</surname><given-names>F.</given-names></name>
<name><surname>Damm</surname><given-names>J.</given-names></name>
<name><surname>Witte</surname><given-names>S.</given-names></name>
<name><surname>Schmidt</surname><given-names>B.</given-names></name>
<name><surname>Benz</surname><given-names>N.</given-names></name>
</person-group><article-title>Clinical use of molecular biomarkers in canine and feline oncology: Current and future</article-title><source>Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci11050199</pub-id><pub-id pub-id-type="pmid">38787171</pub-id>
</element-citation></ref><ref id="B89-vetsci-12-00189"><label>89.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Garcia</surname><given-names>A.P.V.</given-names></name>
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
</person-group><article-title>Prognostic and Predictive Markers in Breast Cancer</article-title><source>Canine and Feline Mammary Pathology: From Diagnosis to Treatment</source><edition>2nd ed.</edition><person-group person-group-type="editor">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><publisher-name>MedVet</publisher-name><publisher-loc>S&#x000e3;o Paulo, Brazil</publisher-loc><year>2023</year><fpage>301</fpage><lpage>319</lpage></element-citation></ref><ref id="B90-vetsci-12-00189"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yersal</surname><given-names>O.</given-names></name>
<name><surname>Barutca</surname><given-names>S.</given-names></name>
</person-group><article-title>Biological subtypes of breast cancer: Prognostic and therapeutic implications</article-title><source>World J. Clin. Oncol.</source><year>2014</year><volume>5</volume><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.5306/wjco.v5.i3.412</pub-id><pub-id pub-id-type="pmid">25114856</pub-id>
</element-citation></ref><ref id="B91-vetsci-12-00189"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gama</surname><given-names>A.</given-names></name>
<name><surname>Alves</surname><given-names>A.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.</given-names></name>
</person-group><article-title>Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: Application of the human classification</article-title><source>Virchows Arch.</source><year>2008</year><volume>453</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s00428-008-0644-3</pub-id><pub-id pub-id-type="pmid">18677512</pub-id>
</element-citation></ref><ref id="B92-vetsci-12-00189"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Cavalcanti</surname><given-names>M.F.</given-names></name>
<name><surname>Schmitt</surname><given-names>F.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours</article-title><source>Vet. Comp. Oncol.</source><year>2009</year><volume>7</volume><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5829.2009.00193.x</pub-id><pub-id pub-id-type="pmid">19891693</pub-id>
</element-citation></ref><ref id="B93-vetsci-12-00189"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Millanta</surname><given-names>F.</given-names></name>
<name><surname>Lazzeri</surname><given-names>G.</given-names></name>
<name><surname>Mazzei</surname><given-names>M.</given-names></name>
<name><surname>Vannozzi</surname><given-names>I.</given-names></name>
<name><surname>Poli</surname><given-names>A.</given-names></name>
</person-group><article-title>MIB-1 labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis</article-title><source>Vet. Path.</source><year>2002</year><volume>39</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1354/vp.39-1-120</pub-id><pub-id pub-id-type="pmid">12102203</pub-id>
</element-citation></ref><ref id="B94-vetsci-12-00189"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Tavares</surname><given-names>W.L.F.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Cox-2 expression in canine mammary carcinomas: Correlation with angiogenesis and overall survival</article-title><source>Vet. Pathol.</source><year>2009</year><volume>46</volume><fpage>1275</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1354/vp.08-VP-0226-C-FL</pub-id><pub-id pub-id-type="pmid">19605908</pub-id>
</element-citation></ref><ref id="B95-vetsci-12-00189"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vieira</surname><given-names>T.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>E.A.</given-names></name>
<name><surname>Santos</surname><given-names>B.J.</given-names></name>
<name><surname>Souza</surname><given-names>F.R.</given-names></name>
<name><surname>Veloso</surname><given-names>E.S.</given-names></name>
<name><surname>Nunes</surname><given-names>C.B.</given-names></name>
<name><surname>Del Puerto</surname><given-names>H.L.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Cox-2 expression in mammary invasive micropapillary carcinoma is associated with prognostic factors and acts as a potential therapeutic target in comparative oncology</article-title><source>Front. Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>983110</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.983110</pub-id><pub-id pub-id-type="pmid">36172611</pub-id>
</element-citation></ref><ref id="B96-vetsci-12-00189"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>L.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Melga&#x000e7;o de Faria</surname><given-names>J.C.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>J.E.</given-names></name>
<name><surname>Dutra</surname><given-names>A.P.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>de Sousa</surname><given-names>L.P.</given-names></name>
<name><surname>Rabelo</surname><given-names>&#x000c9;.M.</given-names></name>
<name><surname>Vieira da Costa</surname><given-names>A.F.</given-names></name>
<etal/>
</person-group><article-title>CA 15.3, CEA and LDH in dogs with malignant mammary tumors</article-title><source>J. Vet. Intern. Med.</source><year>2012</year><volume>26</volume><fpage>1383</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1111/j.1939-1676.2012.01014.x</pub-id><pub-id pub-id-type="pmid">23113715</pub-id>
</element-citation></ref><ref id="B97-vetsci-12-00189"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nascimento</surname><given-names>C.</given-names></name>
<name><surname>Ferreira</surname><given-names>F.</given-names></name>
</person-group><article-title>Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2021</year><volume>1876</volume><elocation-id>188587</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188587</pub-id><pub-id pub-id-type="pmid">34237352</pub-id>
</element-citation></ref><ref id="B98-vetsci-12-00189"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soysal</surname><given-names>S.D.</given-names></name>
<name><surname>Tzankov</surname><given-names>A.</given-names></name>
<name><surname>Muenst</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Role of the tumor microenvironment in breast cancer</article-title><source>Pathobiology</source><year>2015</year><volume>82</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1159/000430499</pub-id><pub-id pub-id-type="pmid">26330355</pub-id>
</element-citation></ref><ref id="B99-vetsci-12-00189"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Place</surname><given-names>A.E.</given-names></name>
<name><surname>Huh</surname><given-names>S.J.</given-names></name>
<name><surname>Polyak</surname><given-names>K.</given-names></name>
</person-group><article-title>The microenvironment in breast cancer progression: Biology and implications for treatment</article-title><source>Breast Cancer Res.</source><year>2011</year><volume>13</volume><fpage>227</fpage><pub-id pub-id-type="doi">10.1186/bcr2912</pub-id><pub-id pub-id-type="pmid">22078026</pub-id>
</element-citation></ref><ref id="B100-vetsci-12-00189"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreira</surname><given-names>M.P.</given-names></name>
<name><surname>Brayner</surname><given-names>F.A.</given-names></name>
<name><surname>Alves</surname><given-names>L.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Silva</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation</article-title><source>Eur. Biophys. J.</source><year>2019</year><volume>48</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1007/s00249-019-01393-0</pub-id><pub-id pub-id-type="pmid">31485678</pub-id>
</element-citation></ref><ref id="B101-vetsci-12-00189"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza Silva</surname><given-names>F.H.</given-names></name>
<name><surname>Underwood</surname><given-names>A.</given-names></name>
<name><surname>Pereira Almeida</surname><given-names>C.</given-names></name>
<name><surname>Mendes Lima</surname><given-names>B.</given-names></name>
<name><surname>Soares Veloso</surname><given-names>E.</given-names></name>
<name><surname>de Carvalho</surname><given-names>B.A.</given-names></name>
<name><surname>Ribeiro</surname><given-names>T.S.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Del Puerto</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Transcription factor SOX3 regulates epithelial-mesenchymal transition in human breast cancer cell line MDAMB-231</article-title><source>Ann. Breast Cancer</source><year>2024</year><volume>7</volume><fpage>1026</fpage></element-citation></ref><ref id="B102-vetsci-12-00189"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulaski</surname><given-names>B.A.</given-names></name>
<name><surname>Ostrand-Rosenberg</surname><given-names>S.</given-names></name>
</person-group><article-title>Mouse 4T1 breast tumor model</article-title><source>Curr. Protoc. Immunol.</source><year>2001</year><volume>39</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/0471142735.im2002s39</pub-id></element-citation></ref><ref id="B103-vetsci-12-00189"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DuPr&#x000e9;</surname><given-names>S.A.</given-names></name>
<name><surname>Redelman</surname><given-names>D.</given-names></name>
<name><surname>Hunter</surname><given-names>K.W.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>The mouse mammary carcinoma 4T1: Characterization of the cellular landscape of primary tumours and metastatic tumour foci</article-title><source>Int. J. Exp. Pathol.</source><year>2007</year><volume>88</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2613.2007.00539.x</pub-id><pub-id pub-id-type="pmid">17877537</pub-id>
</element-citation></ref><ref id="B104-vetsci-12-00189"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dos Reis</surname><given-names>D.C.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>De Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Veloso</surname><given-names>E.S.</given-names></name>
<name><surname>P&#x000ea;gas</surname><given-names>G.R.</given-names></name>
<name><surname>Kraemer</surname><given-names>L.R.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.A.</given-names></name>
<name><surname>Mattos</surname><given-names>M.S.</given-names></name>
<name><surname>Gomes</surname><given-names>D.A.</given-names></name>
<name><surname>Campos</surname><given-names>P.P.</given-names></name>
<etal/>
</person-group><article-title>Versican and tumor-associated macrophages promote tumor progression and metastasis in canine and murine models of breast carcinoma</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><elocation-id>577</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00577</pub-id><pub-id pub-id-type="pmid">31334111</pub-id>
</element-citation></ref><ref id="B105-vetsci-12-00189"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>da Silva</surname><given-names>A.E.</given-names></name>
<name><surname>Serakides</surname><given-names>R.</given-names></name>
<name><surname>Gomes</surname><given-names>M.G.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Ehrlich tumor as a model to study artificial hyperthyroidism influence on breast cancer</article-title><source>Pathol. Res. Pract.</source><year>2007</year><volume>203</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2006.09.005</pub-id><pub-id pub-id-type="pmid">17137730</pub-id>
</element-citation></ref><ref id="B106-vetsci-12-00189"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>C.M.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Ferreira</surname><given-names>M.A.N.D.</given-names></name>
<name><surname>Andrade</surname><given-names>S.P.</given-names></name>
<name><surname>Santos</surname><given-names>I.C.</given-names></name>
<name><surname>Pesquero</surname><given-names>J.L.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Efeito da prote&#x000ed;na Kint3-4 do plasminog&#x000ea;nio humano no crescimento do tumor de Ehrlich</article-title><source>J. Bras. Patol. Med. Lab.</source><year>2011</year><volume>47</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1590/S1676-24442011000400012</pub-id></element-citation></ref><ref id="B107-vetsci-12-00189"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soares</surname><given-names>D.C.F.</given-names></name>
<name><surname>Cardoso</surname><given-names>V.N.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.B.</given-names></name>
<name><surname>Souza</surname><given-names>C.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
<name><surname>Ramaldes</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Antitumoral activity and toxicity of PEG-coated and PEG-folate-coated pH-sensitive liposomes containing 159Gd-DTPA-BMA in Ehrlich tumor-bearing mice</article-title><source>Eur. J. Pharm. Sci.</source><year>2012</year><volume>45</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.018</pub-id><pub-id pub-id-type="pmid">22079137</pub-id>
</element-citation></ref><ref id="B108-vetsci-12-00189"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>I.L.</given-names></name>
<name><surname>Veloso</surname><given-names>E.S.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>I.N.N.</given-names></name>
<name><surname>Braga</surname><given-names>A.D.</given-names></name>
<name><surname>Lopes</surname><given-names>M.T.P.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Quintanilla</surname><given-names>M.</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>R.T.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
</person-group><article-title>Qa-2 expression levels are related with tumor-infiltrating lymphocytes profile during solid Ehrlich tumor development</article-title><source>Biomed. Pharmacother.</source><year>2017</year><volume>92</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.135</pub-id><pub-id pub-id-type="pmid">28591688</pub-id>
</element-citation></ref><ref id="B109-vetsci-12-00189"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinto</surname><given-names>F.C.</given-names></name>
<name><surname>Menezes</surname><given-names>G.B.</given-names></name>
<name><surname>Moura</surname><given-names>S.A.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Teixeira</surname><given-names>M.M.</given-names></name>
<name><surname>Cara</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Induction of apoptosis in tumor cells as a mechanism of tumor growth reduction in allergic mice</article-title><source>Pathol. Res. Pract.</source><year>2009</year><volume>205</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2009.01.009</pub-id><pub-id pub-id-type="pmid">19268488</pub-id>
</element-citation></ref><ref id="B110-vetsci-12-00189"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>C.M.</given-names></name>
<name><surname>Fonseca de Carvalho</surname><given-names>L.</given-names></name>
<name><surname>da Silva Vieira</surname><given-names>T.</given-names></name>
<name><surname>Ara&#x000fa;jo e Silva</surname><given-names>A.C.</given-names></name>
<name><surname>Paz Lopes</surname><given-names>M.T.</given-names></name>
<name><surname>Alves Neves Diniz Ferreira</surname><given-names>M.</given-names></name>
<name><surname>Passos Andrade</surname><given-names>S.</given-names></name>
<name><surname>Dantas Cassali</surname><given-names>G.</given-names></name>
</person-group><article-title>Thalidomide attenuates mammary cancer-associated inflammation, angiogenesis and tumor growth in mice</article-title><source>Biomed. Pharmacother.</source><year>2012</year><volume>66</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2012.04.005</pub-id><pub-id pub-id-type="pmid">22705333</pub-id>
</element-citation></ref><ref id="B111-vetsci-12-00189"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reis</surname><given-names>D.C.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.A.</given-names></name>
<name><surname>Pinto</surname><given-names>S.G.B.</given-names></name>
<name><surname>Ara&#x000fa;jo e Silva</surname><given-names>A.C.</given-names></name>
<name><surname>Moreira</surname><given-names>G.V.</given-names></name>
<name><surname>Campos</surname><given-names>L.C.</given-names></name>
<name><surname>Campos</surname><given-names>P.P.</given-names></name>
<name><surname>Fialho</surname><given-names>S.L.</given-names></name>
<name><surname>Lopes</surname><given-names>M.T.P.</given-names></name>
<name><surname>Gomes</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of the immunomodulatory activity of thalidomide on tumor-associated macrophages in the 4T1 murine metastatic breast cancer model</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2021</year><volume>73</volume><fpage>1334</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-12125</pub-id></element-citation></ref><ref id="B112-vetsci-12-00189"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Auler</surname><given-names>P.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Campos</surname><given-names>G.</given-names></name>
<name><surname>Dias</surname><given-names>A.P.</given-names></name>
<name><surname>Campos</surname><given-names>C.</given-names></name>
<name><surname>Campos</surname><given-names>L.</given-names></name>
<name><surname>Cassali</surname><given-names>G.</given-names></name>
</person-group><article-title>Myeloid metaplasia in canine mixed mammary tumors: Occurrence and characterization</article-title><source>Vet. Q.</source><year>2011</year><volume>31</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1080/01652176.2011.649371</pub-id><pub-id pub-id-type="pmid">22235891</pub-id>
</element-citation></ref><ref id="B113-vetsci-12-00189"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Ribeiro</surname><given-names>L.G.</given-names></name>
<name><surname>Rabelo</surname><given-names>B.S.</given-names></name>
<name><surname>Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Versican expression in canine carcinomas in benign mixed tumours: Is there an association with clinical pathological factors, invasion and overall survival?</article-title><source>BMC Vet. Res.</source><year>2012</year><volume>8</volume><elocation-id>195</elocation-id><pub-id pub-id-type="doi">10.1186/1746-6148-8-195</pub-id><pub-id pub-id-type="pmid">23082892</pub-id>
</element-citation></ref><ref id="B114-vetsci-12-00189"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Versican expression in myoepithelial cells from carcinomas in canine mixed mammary tumors</article-title><source>Vet. J.</source><year>2014</year><volume>200</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2014.01.013</pub-id><pub-id pub-id-type="pmid">24582132</pub-id>
</element-citation></ref><ref id="B115-vetsci-12-00189"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Figueiredo</surname><given-names>S.H.</given-names></name>
<name><surname>Neto</surname><given-names>R.S.C.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Expression of VCAN and its receptors in canine mammary carcinomas with or without myoepithelial proliferation</article-title><source>Res. Vet. Sci.</source><year>2021</year><volume>140</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2021.08.010</pub-id><pub-id pub-id-type="pmid">34399281</pub-id>
</element-citation></ref><ref id="B116-vetsci-12-00189"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Bosco</surname><given-names>Y.</given-names></name>
<name><surname>Silva</surname><given-names>L.P.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Relationship between the expression of versican and EGFR, HER-2, HER-3 and CD44 in matrix-producing tumours in the canine mammary gland</article-title><source>Histol. Histopathol.</source><year>2016</year><volume>31</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">26666308</pub-id>
</element-citation></ref><ref id="B117-vetsci-12-00189"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<name><surname>Miranda</surname><given-names>F.F.</given-names></name>
<name><surname>Alves</surname><given-names>M.R.</given-names></name>
<name><surname>Rocha</surname><given-names>R.M.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160419</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160419</pub-id><pub-id pub-id-type="pmid">27490467</pub-id>
</element-citation></ref><ref id="B118-vetsci-12-00189"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>M.A.</given-names></name>
<name><surname>Souza</surname><given-names>T.A.</given-names></name>
<name><surname>Pinto</surname><given-names>S.G.B.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Gomes</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Inner nuclear membrane localization of epidermal growth factor receptor (EGFR) in spontaneous canine model of invasive micropapillary carcinoma of the mammary gland</article-title><source>Pathol. Res. Pract.</source><year>2016</year><volume>212</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2015.11.017</pub-id><pub-id pub-id-type="pmid">26944829</pub-id>
</element-citation></ref><ref id="B119-vetsci-12-00189"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>M.A.</given-names></name>
<name><surname>Souza</surname><given-names>T.A.</given-names></name>
<name><surname>Pinto</surname><given-names>S.G.B.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Gomes</surname><given-names>D.A.</given-names></name>
<name><surname>Alves</surname><given-names>M.R.</given-names></name>
<name><surname>Silva</surname><given-names>L.P.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.</given-names></name>
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<etal/>
</person-group><article-title>Characterization of neoplastic cells outlining the cystic space of invasive micropapillary carcinoma of the canine mammary gland</article-title><source>BMC Vet. Res.</source><year>2021</year><volume>17</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-021-02807-y</pub-id><pub-id pub-id-type="pmid">33761962</pub-id>
</element-citation></ref><ref id="B120-vetsci-12-00189"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>A.P.V.</given-names></name>
<name><surname>Reis</surname><given-names>L.A.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Longford</surname><given-names>F.G.J.</given-names></name>
<name><surname>Frey</surname><given-names>J.G.</given-names></name>
<name><surname>de Paula</surname><given-names>A.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Canine mammary cancer tumour behaviour and patient survival time are associated with collagen fibre characteristics</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>5668</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-85104-w</pub-id><pub-id pub-id-type="pmid">33707516</pub-id>
</element-citation></ref><ref id="B121-vetsci-12-00189"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>A.P.V.</given-names></name>
<name><surname>Taborda</surname><given-names>D.Y.O.</given-names></name>
<name><surname>Reis</surname><given-names>L.A.</given-names></name>
<name><surname>de Paula</surname><given-names>A.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Collagen modifications predictive of lymph node metastasis in dogs with carcinoma in mixed tumours</article-title><source>Front. Vet. Sci.</source><year>2024</year><volume>6</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2024.1362693</pub-id><pub-id pub-id-type="pmid">38511192</pub-id>
</element-citation></ref><ref id="B122-vetsci-12-00189"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dou</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Pei</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>H.</given-names></name>
</person-group><article-title>The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1368687</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1368687</pub-id><pub-id pub-id-type="pmid">38487526</pub-id>
</element-citation></ref><ref id="B123-vetsci-12-00189"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>M.I.</given-names></name>
<name><surname>Pires</surname><given-names>I.</given-names></name>
<name><surname>Prada</surname><given-names>J.</given-names></name>
<name><surname>Queiroga</surname><given-names>F.L.</given-names></name>
</person-group><article-title>A role for T-lymphocytes in human breast cancer and in canine mammary tumors</article-title><source>Biomed. Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>130894</elocation-id><pub-id pub-id-type="doi">10.1155/2014/130894</pub-id><pub-id pub-id-type="pmid">24672781</pub-id>
</element-citation></ref><ref id="B124-vetsci-12-00189"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues-Jesus</surname><given-names>J.</given-names></name>
<name><surname>Canadas-Sousa</surname><given-names>A.</given-names></name>
<name><surname>Oliveira</surname><given-names>P.</given-names></name>
<name><surname>Figueira</surname><given-names>A.C.</given-names></name>
<name><surname>Marrinhas</surname><given-names>C.</given-names></name>
<name><surname>Petrucci</surname><given-names>G.N.</given-names></name>
<name><surname>Greg&#x000f3;rio</surname><given-names>H.</given-names></name>
<name><surname>Tinoco</surname><given-names>F.</given-names></name>
<name><surname>Goulart</surname><given-names>A.</given-names></name>
<name><surname>Felga</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Distribution of inflammatory infiltrate in feline mammary lesions: Relationship with clinicopathological features</article-title><source>Vet. Comp. Oncol.</source><year>2024</year><volume>22</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1111/vco.12987</pub-id><pub-id pub-id-type="pmid">38863270</pub-id>
</element-citation></ref><ref id="B125-vetsci-12-00189"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>S.Q.</given-names></name>
<name><surname>Waaijer</surname><given-names>S.J.H.</given-names></name>
<name><surname>Zwager</surname><given-names>M.C.</given-names></name>
<name><surname>de Vries</surname><given-names>E.G.E.</given-names></name>
<name><surname>van der Vegt</surname><given-names>B.</given-names></name>
<name><surname>Schr&#x000f6;der</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Tumor-associated macrophages in breast cancer: Innocent bystander or important player?</article-title><source>Cancer Treat. Rev.</source><year>2018</year><volume>70</volume><fpage>178</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.08.010</pub-id><pub-id pub-id-type="pmid">30227299</pub-id>
</element-citation></ref><ref id="B126-vetsci-12-00189"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osuna-G&#x000f3;mez</surname><given-names>R.</given-names></name>
<name><surname>Arqueros</surname><given-names>C.</given-names></name>
<name><surname>Galano</surname><given-names>C.</given-names></name>
<name><surname>Mulet</surname><given-names>M.</given-names></name>
<name><surname>Zamora</surname><given-names>C.</given-names></name>
<name><surname>Barnadas</surname><given-names>A.</given-names></name>
<name><surname>Vidal</surname><given-names>S.</given-names></name>
</person-group><article-title>Effector mechanisms of CD8+ HLA-DR+ T cells in breast cancer patients who respond to neoadjuvant chemotherapy</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>6167</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13246167</pub-id><pub-id pub-id-type="pmid">34944786</pub-id>
</element-citation></ref><ref id="B127-vetsci-12-00189"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Treilleux</surname><given-names>I.</given-names></name>
<name><surname>Blay</surname><given-names>J.Y.</given-names></name>
<name><surname>Bendriss-Vermare</surname><given-names>N.</given-names></name>
<name><surname>Ray-Coquard</surname><given-names>I.</given-names></name>
<name><surname>Bachelot</surname><given-names>T.</given-names></name>
<name><surname>Guastalla</surname><given-names>J.P.</given-names></name>
<name><surname>Bremond</surname><given-names>A.</given-names></name>
<name><surname>Goddard</surname><given-names>S.</given-names></name>
<name><surname>Pin</surname><given-names>J.-J.</given-names></name>
<name><surname>Barthelemy-Dubois</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Dendritic cell infiltration and prognosis of early stage breast cancer</article-title><source>Clin. Cancer Res.</source><year>2004</year><volume>10</volume><fpage>7466</fpage><lpage>7474</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0684</pub-id><pub-id pub-id-type="pmid">15569976</pub-id>
</element-citation></ref><ref id="B128-vetsci-12-00189"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savas</surname><given-names>P.</given-names></name>
<name><surname>Virassamy</surname><given-names>B.</given-names></name>
<name><surname>Ye</surname><given-names>C.</given-names></name>
<name><surname>Salim</surname><given-names>A.</given-names></name>
<name><surname>Mintoff</surname><given-names>C.P.</given-names></name>
<name><surname>Caramia</surname><given-names>F.</given-names></name>
<name><surname>Salgado</surname><given-names>R.</given-names></name>
<name><surname>Byrne</surname><given-names>D.J.</given-names></name>
<name><surname>Teo</surname><given-names>Z.L.</given-names></name>
<name><surname>Dushyanthen</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>986</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0078-7</pub-id><pub-id pub-id-type="pmid">29942092</pub-id>
</element-citation></ref><ref id="B129-vetsci-12-00189"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noy</surname><given-names>R.</given-names></name>
<name><surname>Pollard</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Tumor-associated macrophages: From mechanisms to therapy</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>49</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.010</pub-id><pub-id pub-id-type="pmid">25035953</pub-id>
</element-citation></ref><ref id="B130-vetsci-12-00189"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Groth</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Weber</surname><given-names>R.</given-names></name>
<name><surname>Fleming</surname><given-names>V.</given-names></name>
<name><surname>Altevogt</surname><given-names>P.</given-names></name>
<name><surname>Utikal</surname><given-names>J.</given-names></name>
<name><surname>Umansky</surname><given-names>V.</given-names></name>
</person-group><article-title>Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression</article-title><source>Br. J. Cancer</source><year>2019</year><volume>120</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/s41416-018-0333-1</pub-id><pub-id pub-id-type="pmid">30413826</pub-id>
</element-citation></ref><ref id="B131-vetsci-12-00189"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Houthuijzen</surname><given-names>J.M.</given-names></name>
<name><surname>Jonkers</surname><given-names>J.</given-names></name>
</person-group><article-title>Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment</article-title><source>Cancer Metastasis Rev.</source><year>2018</year><volume>37</volume><fpage>577</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1007/s10555-018-9768-3</pub-id><pub-id pub-id-type="pmid">30465162</pub-id>
</element-citation></ref><ref id="B132-vetsci-12-00189"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joyce</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Therapeutic targeting of the tumor microenvironment</article-title><source>Cancer Cell</source><year>2005</year><volume>7</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.05.024</pub-id><pub-id pub-id-type="pmid">15950901</pub-id>
</element-citation></ref><ref id="B133-vetsci-12-00189"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tu</surname><given-names>Z.</given-names></name>
<name><surname>Karnoub</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Mesenchymal stem/stromal cells in breast cancer development and management</article-title><source>Semin. Cancer Biol.</source><year>2022</year><volume>86</volume><fpage>81</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.09.002</pub-id><pub-id pub-id-type="pmid">36087857</pub-id>
</element-citation></ref><ref id="B134-vetsci-12-00189"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namazi</surname><given-names>N.</given-names></name>
<name><surname>Irandoost</surname><given-names>P.</given-names></name>
<name><surname>Heshmati</surname><given-names>J.</given-names></name>
<name><surname>Larijani</surname><given-names>B.</given-names></name>
<name><surname>Azadbakht</surname><given-names>L.</given-names></name>
</person-group><article-title>The association between fat mass and the risk of breast cancer: A systematic review and meta-analysis</article-title><source>Clin. Nutr.</source><year>2019</year><volume>38</volume><fpage>1496</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2018.09.013</pub-id><pub-id pub-id-type="pmid">30305235</pub-id>
</element-citation></ref><ref id="B135-vetsci-12-00189"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Dong</surname><given-names>P.</given-names></name>
<name><surname>Ren</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
</person-group><article-title>PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient</article-title><source>J. Cancer</source><year>2016</year><volume>7</volume><fpage>784</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.7150/jca.14549</pub-id><pub-id pub-id-type="pmid">27162536</pub-id>
</element-citation></ref><ref id="B136-vetsci-12-00189"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olkhanud</surname><given-names>P.B.</given-names></name>
<name><surname>Damdinsuren</surname><given-names>B.</given-names></name>
<name><surname>Bodogai</surname><given-names>M.</given-names></name>
<name><surname>Gress</surname><given-names>R.E.</given-names></name>
<name><surname>Sen</surname><given-names>R.</given-names></name>
<name><surname>Wejksza</surname><given-names>K.</given-names></name>
<name><surname>Malchinkhuu</surname><given-names>E.</given-names></name>
<name><surname>Wersto</surname><given-names>R.P.</given-names></name>
<name><surname>Biragyn</surname><given-names>A.</given-names></name>
</person-group><article-title>Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>3505</fpage><lpage>3515</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4316</pub-id><pub-id pub-id-type="pmid">21444674</pub-id>
</element-citation></ref><ref id="B137-vetsci-12-00189"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
</person-group><article-title>Dynamic balance between master transcription factorsdetermines the fates and functions of cd4 T cell and innate lymphoid cell subsets</article-title><source>J. Exp. Med.</source><year>2017</year><volume>214</volume><fpage>1861</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1084/jem.20170494</pub-id><pub-id pub-id-type="pmid">28630089</pub-id>
</element-citation></ref><ref id="B138-vetsci-12-00189"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fridlender</surname><given-names>Z.G.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Kapoor</surname><given-names>V.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Ling</surname><given-names>L.</given-names></name>
<name><surname>Worthen</surname><given-names>G.S.</given-names></name>
<name><surname>Albelda</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Polarization of tumor-associated neutrophil phenotype by TGF-beta: &#x0201c;N1&#x0201d; versus &#x0201c;N2&#x0201d; TAN</article-title><source>Cancer Cell</source><year>2009</year><volume>16</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.06.017</pub-id><pub-id pub-id-type="pmid">19732719</pub-id>
</element-citation></ref><ref id="B139-vetsci-12-00189"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salgado</surname><given-names>R.</given-names></name>
<name><surname>Denkert</surname><given-names>C.</given-names></name>
<name><surname>Campbell</surname><given-names>C.</given-names></name>
<name><surname>Savas</surname><given-names>P.</given-names></name>
<name><surname>Nuciforo</surname><given-names>P.</given-names></name>
<name><surname>Aura</surname><given-names>C.</given-names></name>
<name><surname>de Azambuja</surname><given-names>E.</given-names></name>
<name><surname>Eidtmann</surname><given-names>H.</given-names></name>
<name><surname>Ellis</surname><given-names>C.E.</given-names></name>
<name><surname>Baselga</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Tumour-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial</article-title><source>JAMA Oncol.</source><year>2015</year><volume>1</volume><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.0830</pub-id><pub-id pub-id-type="pmid">26181252</pub-id>
</element-citation></ref><ref id="B140-vetsci-12-00189"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Bairi</surname><given-names>K.</given-names></name>
<name><surname>Haynes</surname><given-names>H.R.</given-names></name>
<name><surname>Blackley</surname><given-names>E.</given-names></name>
<name><surname>Fineberg</surname><given-names>S.</given-names></name>
<name><surname>Shear</surname><given-names>J.</given-names></name>
<name><surname>Turner</surname><given-names>S.</given-names></name>
<name><surname>de Freitas</surname><given-names>J.R.</given-names></name>
<name><surname>Sur</surname><given-names>D.</given-names></name>
<name><surname>Amendola</surname><given-names>L.C.</given-names></name>
<name><surname>Gharib</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group</article-title><source>npj Breast Cancer</source><year>2021</year><volume>7</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1038/s41523-021-00346-1</pub-id><pub-id pub-id-type="pmid">34853355</pub-id>
</element-citation></ref><ref id="B141-vetsci-12-00189"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Chon</surname><given-names>S.K.</given-names></name>
<name><surname>Im</surname><given-names>K.S.</given-names></name>
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Sur</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study</article-title><source>Can. J. Vet. Res.</source><year>2013</year><volume>77</volume><fpage>142</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24082407</pub-id>
</element-citation></ref><ref id="B142-vetsci-12-00189"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dagher</surname><given-names>E.</given-names></name>
<name><surname>Simbault</surname><given-names>L.</given-names></name>
<name><surname>Abadie</surname><given-names>J.</given-names></name>
<name><surname>Loussouarn</surname><given-names>D.</given-names></name>
<name><surname>Campone</surname><given-names>M.</given-names></name>
<name><surname>Nguyen</surname><given-names>F.</given-names></name>
</person-group><article-title>Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer</article-title><source>Tumor Biol.</source><year>2020</year><volume>42</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1177/1010428319901052</pub-id><pub-id pub-id-type="pmid">31959092</pub-id>
</element-citation></ref><ref id="B143-vetsci-12-00189"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrucci</surname><given-names>G.N.</given-names></name>
<name><surname>Lobo</surname><given-names>L.</given-names></name>
<name><surname>Queiroga</surname><given-names>F.</given-names></name>
<name><surname>Martins</surname><given-names>J.</given-names></name>
<name><surname>Prada</surname><given-names>J.</given-names></name>
<name><surname>Pires</surname><given-names>I.</given-names></name>
<name><surname>Henriques</surname><given-names>J.</given-names></name>
</person-group><article-title>Neutrophil-to-lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas</article-title><source>Vet. Comp. Oncol.</source><year>2021</year><volume>19</volume><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1111/vco.12686</pub-id><pub-id pub-id-type="pmid">33576562</pub-id>
</element-citation></ref><ref id="B144-vetsci-12-00189"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Granot</surname><given-names>Z.</given-names></name>
<name><surname>Henke</surname><given-names>E.</given-names></name>
<name><surname>Comen</surname><given-names>E.A.</given-names></name>
<name><surname>King</surname><given-names>T.A.</given-names></name>
<name><surname>Norton</surname><given-names>L.</given-names></name>
<name><surname>Benezra</surname><given-names>R.</given-names></name>
</person-group><article-title>Tumor-entrained neutrophils inhibit seeding in the premetastatic lung</article-title><source>Cancer Cell</source><year>2011</year><volume>20</volume><fpage>300</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.08.012</pub-id><pub-id pub-id-type="pmid">21907922</pub-id>
</element-citation></ref><ref id="B145-vetsci-12-00189"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Costa</surname><given-names>I.B.</given-names></name>
<name><surname>Silva</surname><given-names>L.P.</given-names></name>
<name><surname>Fernandes</surname><given-names>D.M.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>P.R.</given-names></name>
<name><surname>Pinto</surname><given-names>S.G.B.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><elocation-id>256</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-10-256</pub-id><pub-id pub-id-type="pmid">20525350</pub-id>
</element-citation></ref><ref id="B146-vetsci-12-00189"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>T.A.</given-names></name>
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<name><surname>Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Lopes</surname><given-names>M.T.</given-names></name>
<name><surname>Ferreira</surname><given-names>M.A.</given-names></name>
<name><surname>Andrade</surname><given-names>S.P.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Relationship between the inflammatory tumor microenvironment and different histologic types of canine mammary tumors</article-title><source>Res. Vet. Sci.</source><year>2018</year><volume>119</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2018.06.012</pub-id><pub-id pub-id-type="pmid">29966962</pub-id>
</element-citation></ref><ref id="B147-vetsci-12-00189"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vieira-Filho</surname><given-names>C.H.C.</given-names></name>
<name><surname>Gomes</surname><given-names>D.A.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.A.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
</person-group><article-title>Tumor-associated macrophage is correlated with survival and SOCS protein expression in canine mammary carcinoma</article-title><source>Pesqui. Vet. Bras.</source><year>2018</year><volume>38</volume><fpage>1972</fpage><lpage>1980</lpage><pub-id pub-id-type="doi">10.1590/1678-5150-pvb-5638</pub-id></element-citation></ref><ref id="B148-vetsci-12-00189"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monteiro</surname><given-names>L.N.</given-names></name>
<name><surname>Sousa</surname><given-names>R.S.</given-names></name>
<name><surname>Almeida</surname><given-names>J.M.</given-names></name>
<name><surname>Gamba</surname><given-names>C.O.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Tumour-associated macrophages: Relation with progression and invasiveness, and assessment of M1/M2 macrophages in canine mammary tumours</article-title><source>Vet. J.</source><year>2018</year><volume>234</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2018.02.016</pub-id><pub-id pub-id-type="pmid">29680383</pub-id>
</element-citation></ref><ref id="B149-vetsci-12-00189"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>K.A.</given-names></name>
<name><surname>Serakides</surname><given-names>R.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Ribeiro</surname><given-names>A.P.</given-names></name>
<name><surname>Fonseca</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0267648</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0267648</pub-id><pub-id pub-id-type="pmid">35512031</pub-id>
</element-citation></ref><ref id="B150-vetsci-12-00189"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flecher</surname><given-names>M.C.</given-names></name>
<name><surname>Balabram</surname><given-names>D.</given-names></name>
<name><surname>Salles</surname><given-names>Y.A.</given-names></name>
<name><surname>Souza</surname><given-names>F.R.</given-names></name>
<name><surname>Estrela-Lima</surname><given-names>A.</given-names></name>
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Evaluation of immunophenotype and inflammation in canine mammary neoplasms with solid arrangement</article-title><source>J. Comp. Pathol.</source><year>2024</year><volume>213</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2024.06.004</pub-id><pub-id pub-id-type="pmid">39018987</pub-id>
</element-citation></ref><ref id="B151-vetsci-12-00189"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Day</surname><given-names>C.</given-names></name>
<name><surname>Merlino</surname><given-names>G.</given-names></name>
<name><surname>Dyke</surname><given-names>T.V.</given-names></name>
</person-group><article-title>Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>39</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.068</pub-id><pub-id pub-id-type="pmid">26406370</pub-id>
</element-citation></ref><ref id="B152-vetsci-12-00189"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Maria</surname><given-names>W.S.</given-names></name>
<name><surname>Caliari</surname><given-names>M.V.</given-names></name>
<name><surname>Leite</surname><given-names>V.H.R.</given-names></name>
</person-group><article-title>Mammary adenocarcinoma of viral genesis in CF-1 mice</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>1995</year><volume>47</volume><fpage>721</fpage><lpage>725</lpage></element-citation></ref><ref id="B153-vetsci-12-00189"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singhal</surname><given-names>S.</given-names></name>
<name><surname>Mehta</surname><given-names>J.</given-names></name>
<name><surname>Desikan</surname><given-names>R.</given-names></name>
<name><surname>Ayers</surname><given-names>D.</given-names></name>
<name><surname>Roberson</surname><given-names>P.</given-names></name>
<name><surname>Eddlemon</surname><given-names>P.</given-names></name>
<name><surname>Munshi</surname><given-names>N.</given-names></name>
<name><surname>Anaissie</surname><given-names>E.</given-names></name>
<name><surname>Wilson</surname><given-names>C.</given-names></name>
<name><surname>Dhodapkar</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Antitumor activity of thalidomide in refractory multiple myeloma</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>341</volume><fpage>1565</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1056/NEJM199911183412102</pub-id><pub-id pub-id-type="pmid">10564685</pub-id>
</element-citation></ref><ref id="B154-vetsci-12-00189"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez-Millan</surname><given-names>B.</given-names></name>
<name><surname>Diaz de la Guardia</surname><given-names>R.</given-names></name>
<name><surname>Roca-Ho</surname><given-names>H.</given-names></name>
<name><surname>Casado</surname><given-names>P.</given-names></name>
<name><surname>Navarro</surname><given-names>P.</given-names></name>
<name><surname>Espinosa</surname><given-names>G.</given-names></name>
<name><surname>Ca&#x000f1;ete</surname><given-names>A.</given-names></name>
<name><surname>Alonso</surname><given-names>M.</given-names></name>
<name><surname>Salcedo</surname><given-names>M.</given-names></name>
<name><surname>Fernandez</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease</article-title><source>Exp. Mol. Med.</source><year>2017</year><volume>49</volume><fpage>e290</fpage><pub-id pub-id-type="doi">10.1038/emm.2016.143</pub-id><pub-id pub-id-type="pmid">28154372</pub-id>
</element-citation></ref><ref id="B155-vetsci-12-00189"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reis</surname><given-names>D.C.</given-names></name>
<name><surname>Souza</surname><given-names>C.M.</given-names></name>
<name><surname>Campos</surname><given-names>L.C.</given-names></name>
<name><surname>Ara&#x000fa;jo e Silva</surname><given-names>A.C.</given-names></name>
<name><surname>Paz Lopes</surname><given-names>M.T.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
</person-group><article-title>Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma</article-title><source>Bras. Patol. Med. Lab.</source><year>2014</year><volume>50</volume><fpage>64</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1590/S1676-24442014000100009</pub-id></element-citation></ref><ref id="B156-vetsci-12-00189"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>C.B.D.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Monteiro</surname><given-names>L.N.</given-names></name>
<name><surname>Pegas</surname><given-names>G.R.A.</given-names></name>
<name><surname>Fialho</surname><given-names>S.L.</given-names></name>
<name><surname>Balabram</surname><given-names>D.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms</article-title><source>In Vivo</source><year>2018</year><volume>32</volume><fpage>1659</fpage><lpage>1666</lpage><pub-id pub-id-type="doi">10.21873/invivo.11429</pub-id><pub-id pub-id-type="pmid">30348731</pub-id>
</element-citation></ref><ref id="B157-vetsci-12-00189"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baidas</surname><given-names>S.M.</given-names></name>
<name><surname>Winer</surname><given-names>E.P.</given-names></name>
<name><surname>Fleming</surname><given-names>G.F.</given-names></name>
<name><surname>Harris</surname><given-names>L.</given-names></name>
<name><surname>Pluda</surname><given-names>J.M.</given-names></name>
<name><surname>Crawford</surname><given-names>J.G.</given-names></name>
<name><surname>Yamauchi</surname><given-names>H.</given-names></name>
<name><surname>Isaacs</surname><given-names>C.</given-names></name>
<name><surname>Hanfelt</surname><given-names>J.</given-names></name>
<name><surname>Tefft</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Phase II evaluation of thalidomide in patients with metastatic breast cancer</article-title><source>J. Clin. Oncol.</source><year>2000</year><volume>18</volume><fpage>2710</fpage><lpage>2717</lpage><pub-id pub-id-type="doi">10.1200/JCO.2000.18.14.2710</pub-id><pub-id pub-id-type="pmid">10894870</pub-id>
</element-citation></ref><ref id="B158-vetsci-12-00189"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>A.E.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.</given-names></name>
<name><surname>Ocarino</surname><given-names>N.M.</given-names></name>
<name><surname>Moraes</surname><given-names>J.R.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Serakides</surname><given-names>R.</given-names></name>
</person-group><article-title>Effect of hypothyroidism on growth, viability and characteristics of ascite Ehrlich tumor cells in ovariectomized and non-ovariectomized mice</article-title><source>J. Appl. Res.</source><year>2007</year><volume>7</volume><fpage>2</fpage></element-citation></ref><ref id="B159-vetsci-12-00189"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ver&#x000e7;osa Junior</surname><given-names>D.</given-names></name>
<name><surname>Melo</surname><given-names>M.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Dantas-Barros</surname><given-names>A.M.</given-names></name>
<name><surname>Silva</surname><given-names>P.G.P.J.</given-names></name>
</person-group><article-title>Influence of Agaricus blazei Murril in solid Ehrlich tumor and popliteal lymph nodes in mice</article-title><source>Arq. Bras. Med. Vet. Zootec.</source><year>2007</year><volume>59</volume><fpage>150</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1590/S0102-09352007000100025</pub-id></element-citation></ref><ref id="B160-vetsci-12-00189"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>N.C.R.</given-names></name>
<name><surname>Silva</surname><given-names>Y.O.B.</given-names></name>
<name><surname>Takahashi</surname><given-names>J.A.</given-names></name>
<name><surname>Andrade</surname><given-names>S.P.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>de Oliveira</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Dietary lipids management: Are there any benefits from the prevention and treatment of 4T1 murine breast carcinoma?</article-title><source>An. Acad. Bras. Cienc.</source><year>2023</year><volume>95</volume><fpage>e20210330</fpage><pub-id pub-id-type="pmid">37585893</pub-id>
</element-citation></ref><ref id="B161-vetsci-12-00189"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>C.M.</given-names></name>
<name><surname>Ara&#x000fa;jo e Silva</surname><given-names>A.C.</given-names></name>
<name><surname>de Jesus Ferraciolli</surname><given-names>C.</given-names></name>
<name><surname>Moreira</surname><given-names>G.V.</given-names></name>
<name><surname>Campos</surname><given-names>L.C.</given-names></name>
<name><surname>dos Reis</surname><given-names>D.C.</given-names></name>
<name><surname>Lopes</surname><given-names>M.T.</given-names></name>
<name><surname>Ferreira</surname><given-names>M.A.</given-names></name>
<name><surname>Andrade</surname><given-names>S.P.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model</article-title><source>Biomed. Pharmacother.</source><year>2014</year><volume>68</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2013.08.004</pub-id><pub-id pub-id-type="pmid">24054045</pub-id>
</element-citation></ref><ref id="B162-vetsci-12-00189"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>D.R.</given-names></name>
<name><surname>Fialho</surname><given-names>A.L.</given-names></name>
<name><surname>Pereira</surname><given-names>M.M.</given-names></name>
<name><surname>Martins</surname><given-names>M.F.A.</given-names></name>
<name><surname>Nunes</surname><given-names>M.C.M.</given-names></name>
<name><surname>Paula</surname><given-names>F.S.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Avalia&#x000e7;&#x000e3;o nutricional de pacientes com c&#x000e2;ncer de mama atendidas no Servi&#x000e7;o de Mastologia do Hospital das Cl&#x000ed;nicas, Belo Horizonte (MG), Brasil</article-title><source>Ci&#x000ea;nc. Sa&#x000fa;de Coletiva</source><year>2014</year><volume>19</volume><fpage>1573</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1590/1413-81232014195.02262013</pub-id><pub-id pub-id-type="pmid">24897222</pub-id>
</element-citation></ref><ref id="B163-vetsci-12-00189"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azrad</surname><given-names>M.</given-names></name>
<name><surname>Demark-Wahnefried</surname><given-names>W.</given-names></name>
</person-group><article-title>The association between adiposity and breast cancer recurrence and survival: A review of the recent literature</article-title><source>Curr. Nutr. Rep.</source><year>2014</year><volume>3</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s13668-013-0068-9</pub-id><pub-id pub-id-type="pmid">24533234</pub-id>
</element-citation></ref><ref id="B164-vetsci-12-00189"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>R.S.</given-names></name>
<name><surname>Silva</surname><given-names>J.O.</given-names></name>
<name><surname>Monteiro</surname><given-names>L.O.F.</given-names></name>
<name><surname>Leite</surname><given-names>E.A.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Rubello</surname><given-names>D.</given-names></name>
<name><surname>Cardoso</surname><given-names>V.N.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.A.M.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
<name><surname>de Barros</surname><given-names>A.L.B.</given-names></name>
</person-group><article-title>Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy</article-title><source>Biomed. Pharmacother.</source><year>2016</year><volume>84</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.09.032</pub-id><pub-id pub-id-type="pmid">27664949</pub-id>
</element-citation></ref><ref id="B165-vetsci-12-00189"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>R.S.</given-names></name>
<name><surname>Silva</surname><given-names>J.O.</given-names></name>
<name><surname>Mussi</surname><given-names>S.V.</given-names></name>
<name><surname>Lopes</surname><given-names>S.C.A.</given-names></name>
<name><surname>Leite</surname><given-names>E.A.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Cardoso</surname><given-names>V.N.</given-names></name>
<name><surname>Townsend</surname><given-names>D.M.</given-names></name>
<name><surname>Colletti</surname><given-names>P.M.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.A.M.</given-names></name>
<etal/>
</person-group><article-title>Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model</article-title><source>Mol. Imaging Biol.</source><year>2018</year><volume>20</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1007/s11307-017-1133-3</pub-id><pub-id pub-id-type="pmid">29043471</pub-id>
</element-citation></ref><ref id="B166-vetsci-12-00189"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rocha</surname><given-names>T.G.</given-names></name>
<name><surname>Lopes</surname><given-names>S.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Ferreira</surname><given-names>&#x000ca;.</given-names></name>
<name><surname>Veloso</surname><given-names>E.S.</given-names></name>
<name><surname>Leite</surname><given-names>E.A.</given-names></name>
<name><surname>Braga</surname><given-names>F.C.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.A.</given-names></name>
<name><surname>Balvay</surname><given-names>D.</given-names></name>
<name><surname>Garofalakis</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma</article-title><source>Integr. Cancer Ther.</source><year>2016</year><volume>15</volume><fpage>512</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1177/1534735416628273</pub-id><pub-id pub-id-type="pmid">27130721</pub-id>
</element-citation></ref><ref id="B167-vetsci-12-00189"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>M.S.</given-names></name>
<name><surname>Roque</surname><given-names>M.C.</given-names></name>
<name><surname>de Barros</surname><given-names>A.L.B.</given-names></name>
<name><surname>de Oliveira Silva</surname><given-names>J.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>109</volume><fpage>1728</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.011</pub-id><pub-id pub-id-type="pmid">30551427</pub-id>
</element-citation></ref><ref id="B168-vetsci-12-00189"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boratto</surname><given-names>F.A.</given-names></name>
<name><surname>Franco</surname><given-names>M.S.</given-names></name>
<name><surname>Barros</surname><given-names>A.L.B.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>Malachias</surname><given-names>A.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.A.M.</given-names></name>
<name><surname>Leite</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>144</volume><fpage>105205</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105205</pub-id><pub-id pub-id-type="pmid">31874285</pub-id>
</element-citation></ref><ref id="B169-vetsci-12-00189"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lages</surname><given-names>E.B.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.S.</given-names></name>
<name><surname>Silva</surname><given-names>J.O.</given-names></name>
<name><surname>de Souza</surname><given-names>&#x000c2;.M.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>de Barros</surname><given-names>A.L.B.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.A.M.</given-names></name>
</person-group><article-title>Co-delivery of doxorubicin, docosahexaenoic acid, and &#x003b1;-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>132</volume><elocation-id>110876</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110876</pub-id><pub-id pub-id-type="pmid">33113428</pub-id>
</element-citation></ref><ref id="B170-vetsci-12-00189"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paschoal Barbosa</surname><given-names>L.M.</given-names></name>
<name><surname>Gomes</surname><given-names>E.R.</given-names></name>
<name><surname>de Barros</surname><given-names>A.L.B.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
<name><surname>de Carvalho</surname><given-names>A.T.</given-names></name>
<name><surname>Silva</surname><given-names>J.O.</given-names></name>
<name><surname>P&#x000e1;dua</surname><given-names>A.L.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Hybrid Nanosystem Formed by DOX-Loaded Liposomes and Extracellular Vesicles from MDA-MB-231 Is Effective against Breast Cancer Cells with Different Molecular Profiles</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>739</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16060739</pub-id><pub-id pub-id-type="pmid">38931861</pub-id>
</element-citation></ref><ref id="B171-vetsci-12-00189"><label>171.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Sorenmo</surname><given-names>K.U.</given-names></name>
<name><surname>Worley</surname><given-names>D.R.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Tumors of the Mammary Gland</article-title><source>Withrow &#x00026; MacEwen&#x02019;s Small Animal Clinical Oncology</source><edition>5th ed.</edition><person-group person-group-type="editor">
<name><surname>Withrow</surname><given-names>S.J.</given-names></name>
<name><surname>Vail</surname><given-names>D.M.</given-names></name>
<name><surname>Page</surname><given-names>R.L.</given-names></name>
</person-group><publisher-name>Elsevier Saunders</publisher-name><publisher-loc>Saint Louis, MO, USA</publisher-loc><year>2013</year><fpage>538</fpage><lpage>556</lpage></element-citation></ref><ref id="B172-vetsci-12-00189"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>de Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Bertagnolli</surname><given-names>A.C.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors</article-title><source>In Vivo</source><year>2012</year><volume>26</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">22523289</pub-id>
</element-citation></ref><ref id="B173-vetsci-12-00189"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campos</surname><given-names>C.B.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Lavalle</surname><given-names>G.E.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging</article-title><source>In Vivo</source><year>2014</year><volume>28</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">25189900</pub-id>
</element-citation></ref><ref id="B174-vetsci-12-00189"><label>174.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rodrigues</surname><given-names>A.C.B.</given-names></name>
<name><surname>Nunes</surname><given-names>F.C.</given-names></name>
<name><surname>Sueiro</surname><given-names>F.A.R.</given-names></name>
<name><surname>Nakagaki</surname><given-names>K.Y.R.</given-names></name>
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Aspectos epidemiol&#x000f3;gicos das neoplasias mam&#x000e1;rias em cadelas e gatas</article-title><source>Patologia Mam&#x000e1;ria Canina e Felina: Do Diagn&#x000f3;stico ao Tratamento</source><edition>2nd ed.</edition><person-group person-group-type="editor">
<name><surname>Cassali</surname><given-names>G.D.</given-names></name>
</person-group><publisher-name>MedVet</publisher-name><publisher-loc>S&#x000e3;o Paulo, Brazil</publisher-loc><year>2023</year><fpage>22</fpage><lpage>64</lpage></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00189-f001"><label>Figure 1</label><caption><p>Interactive conceptual network of the main research themes in breast cancer, produced via bibliometric analysis of the articles published by the group.</p></caption><graphic xlink:href="vetsci-12-00189-g001" position="float"/></fig><fig position="float" id="vetsci-12-00189-f002"><label>Figure 2</label><caption><p>Graphic representations and photomicrographs of the most frequent histological types in humans, canines, and felines. (<bold>A</bold>). Invasive carcinoma (human). (<bold>B</bold>). Carcinoma in a mixed tumor (canine). (<bold>C</bold>). Cribriform carcinoma (feline). Created with <uri>BioRender.com</uri> (accessed on 16 February 2025).</p></caption><graphic xlink:href="vetsci-12-00189-g002" position="float"/></fig><fig position="float" id="vetsci-12-00189-f003"><label>Figure 3</label><caption><p>Graphical representation of the favorable and unfavorable prognostic aspects of the tumoral microenvironment in humans, canines, felines, and mice, representing the anatomical aspects of the mammary gland and regional lymph nodes.</p></caption><graphic xlink:href="vetsci-12-00189-g003" position="float"/></fig><table-wrap position="float" id="vetsci-12-00189-t001"><object-id pub-id-type="pii">vetsci-12-00189-t001_Table 1</object-id><label>Table 1</label><caption><p>Histological types described in women and identified in female dogs and/or cats based on the WHO classification [<xref rid="B21-vetsci-12-00189" ref-type="bibr">21</xref>] and the Consensus Regarding the Diagnosis, Prognosis, and Treatment of Canine Mammary Tumors, for dogs and cats [<xref rid="B14-vetsci-12-00189" ref-type="bibr">14</xref>,<xref rid="B16-vetsci-12-00189" ref-type="bibr">16</xref>,<xref rid="B32-vetsci-12-00189" ref-type="bibr">32</xref>,<xref rid="B34-vetsci-12-00189" ref-type="bibr">34</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Woman</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dog</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cat</th></tr></thead><tbody><tr><td rowspan="8" align="center" valign="middle" colspan="1">
<bold>BENIGN</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ductal adenoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tubular adenoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lactating adenoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ductal papilloma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adenomyoepithelioma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fibroadenoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Benign phyllodes tumor</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pleomorphic adenoma/benign mixed tumor</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td rowspan="14" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>MALIGNANT</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Invasive carcinoma of no special type</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x *</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ductal carcinoma in situ</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tubular carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Invasive papillary carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Solid papillary carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cribriform carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Invasive micropapillary carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pleomorphic lobular carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Secretory carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metaplastic carcinoma/carcinoma in a mixed tumor</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malignant adenomyoepithelioma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mucinous carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neuroendocrine carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">x</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carcinoma with apocrine differentiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td></tr></tbody></table><table-wrap-foot><fn><p>* Solid-pattern carcinoma is equivalent to an invasive carcinoma of no special type with histological grade III. x = Histological type found in this species. - = Histological type not found in this species.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00189-t002"><object-id pub-id-type="pii">vetsci-12-00189-t002_Table 2</object-id><label>Table 2</label><caption><p>Prognostic and predictive factors for canine, feline, and human mammary neoplasms [<xref rid="B54-vetsci-12-00189" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-12-00189" ref-type="bibr">55</xref>,<xref rid="B62-vetsci-12-00189" ref-type="bibr">62</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Woman</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dog</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cat</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PROGNOSTIC</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Clinical staging (TNM)</td><td align="center" valign="middle" rowspan="1" colspan="1">Clinical staging (TNM)</td><td align="center" valign="middle" rowspan="1" colspan="1">Clinical staging (TNM)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Tumoral size</td><td align="center" valign="middle" rowspan="1" colspan="1">Tumoral size</td><td align="center" valign="middle" rowspan="1" colspan="1">Tumoral size</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Lymph node metastasis</td><td align="center" valign="middle" rowspan="1" colspan="1">Lymph node metastasis</td><td align="center" valign="middle" rowspan="1" colspan="1">Lymph node metastasis</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological type</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological type</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological type</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological grading</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological grading</td><td align="center" valign="middle" rowspan="1" colspan="1">Histological grading</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal receptors (ER, PR*)</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal receptors (ER, PR*)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">HER-2</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">HER-2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Molecular profile</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cox-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cox-2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>PREDICTIVE</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal receptors (ER, PR*)</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal receptors (ER, PR*)</td><td align="center" valign="middle" rowspan="1" colspan="1">Hormonal receptors (ER, PR*)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td><td align="center" valign="middle" rowspan="1" colspan="1">Ki67</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Her-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cox-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cox2</td></tr></tbody></table><table-wrap-foot><fn><p>ER: estrogen receptor; PR*: progesterone receptor. Further studies with larger sample sizes are necessary.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00189-t003"><object-id pub-id-type="pii">vetsci-12-00189-t003_Table 3</object-id><label>Table 3</label><caption><p>Immunophenotypic classification of mammary neoplasms in dogs [<xref rid="B41-vetsci-12-00189" ref-type="bibr">41</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Luminal A</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Luminal B</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">HER-2 Overexpressed</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Triple Negative/Basal Like</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER-2 &#x02212;</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER-2 +</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">ER</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou PR+</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou PR+</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou PR+</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PR</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou ER+</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou ER+</td><td align="center" valign="middle" rowspan="1" colspan="1">+ e/ou ER+</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HER-2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ki-67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;20%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;20%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS</td></tr></tbody></table><table-wrap-foot><fn><p>ER: estrogen receptor; PR: progesterone receptor; AS: any score.</p></fn></table-wrap-foot></table-wrap></floats-group></article>